PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION
Notice of 2025 Annual Meeting of Stockholders
Thursday, April 24, 2025
9:00 a.m., Eastern Time
Via Virtual Meeting Format
The 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Enviri Corporation (the “Company”) will be held on Thursday, April 24, 2025, beginning at 9:00 a.m., Eastern Time via the Internet at https://meetnow.global/MTYYVCA. Stockholders and others will not be able to attend the Annual Meeting in person. Any reference in this Proxy Statement to attending the Annual Meeting, including any reference to “in person” attendance, means attending by remote communication via live webcast on the Internet.
The purposes of the meeting are as follows:
1. |
To elect the eight nominees named in the Proxy Statement to serve as Directors until the 2026 Annual Meeting of Stockholders; |
2. |
To ratify the appointment of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2025; |
3. |
To vote, on an advisory basis, to approve the compensation of the Company’s named executive officers; |
4. |
To vote on Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan; |
5. |
To vote on Amendment No. 3 to the 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan; |
6. |
To vote on an Amendment to the Certificate of Incorporation to provide for Officer Exculpation; and |
7. |
To conduct such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. |
The Proxy Statement accompanying this Notice of 2025 Annual Meeting of Stockholders describes each of these items in detail. In addition, the Proxy Statement contains other important information that you should read and consider before you vote.
The Board of Directors of the Company has fixed the close of business on February 24, 2025 as the record date for the determination of stockholders who are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof.
The Company is furnishing proxy materials over the Internet as permitted under the “notice and access” rules of the Securities and Exchange Commission. Under these rules, many of the Company’s stockholders will receive a Notice of Internet Availability of Proxy Materials instead of a paper copy of the Notice of 2025 Annual Meeting of Stockholders and Proxy Statement, our Proxy Card, our Annual Report on Form 10-K, and the Letter from our Chairman & CEO. We believe this process allows us to provide our stockholders with the information they need while lowering the costs of printing and distributing proxy materials. Stockholders who do not receive a Notice of Internet Availability of Proxy Materials will receive a paper copy of the proxy materials by mail.
Your vote is very important to us, and we encourage you to vote your shares as soon as possible, whether or not you plan to attend the Annual Meeting. Information about how to vote your shares via the Internet, by telephone, or by signing, dating, and returning your Proxy Card can be found in the enclosed Proxy Statement.
By order of the Board of Directors,
Russell C. Hochman
Senior Vice President and General Counsel, Chief Compliance Officer & Corporate Secretary
March [•], 2025
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on April 24, 2025. The Notice of 2025 Annual Meeting of Stockholders and Proxy Statement, our Proxy Card, our Annual Report on Form 10-K, and the Letter from our Chairman & CEO are available free of charge at www.envisionreports.com/NVRI (for registered stockholders) or www.edocumentview.com/NVRI (for all other stockholders), or by calling toll-free (866) 641-4276.
|
|
|
|
|
2025 Proxy Statement 1 |
The Board of Directors
General Oversight
The Board has general oversight responsibility for the Company’s affairs. Although the Board does not have responsibility for day-to-day management of the Company, Board members stay informed about the Company’s business through regular meetings, site visits, and other periodic interactions with management and stakeholders. The Board is deeply involved in the strategic planning process for the Company and each of its business divisions. The Board also plays an important oversight role in the Company’s risk management, leadership development, and succession planning processes.
Composition
The Board is currently comprised of nine Directors, eight of whom qualify as independent.
As part of our longstanding commitment to good corporate governance practices, we continue to refresh our Board composition to ensure our Directors have the right mix of backgrounds, skills, and experiences to support the strategic direction of Enviri. In furtherance of this objective, our Board has nominated Nicholas C. Fanandakis, a highly accomplished executive, as the Company’s newest independent Director in connection with the Annual Meeting.
Furthermore, our Independent Lead Director, David C. Everitt, and Phillip C. Widman, a member of our Audit and Governance committees, will retire in connection with the Annual Meeting. In addition, the Company expects to continue to make changes to its Board in 2026 as part of its Board refreshment program.
Enviri has refreshed its Board with three new members within the last four years and, following these anticipated changes, our independent Directors will have an average tenure of less than 6 years.
There are no family relationships among any of the Directors, or between any Director and any of the Company’s executive officers. In accordance with the Board’s Corporate Governance Principles and applicable sections of the NYSE Listed Company Manual (the “NYSE Rules”), the independent Directors regularly meet in executive session. These meetings allow the independent Directors to discuss important issues, including the business and affairs of the Company as well as matters concerning management, without any member of management present. During the 2024 fiscal year, the independent Directors held five meetings.
Leadership Structure
The Company’s governance documents provide the Board with flexibility to select the leadership structure that is most appropriate for the Company and its stockholders. The Board regularly evaluates the Company’s leadership structure and has concluded that the Company and its stockholders are best served by not having a formal policy regarding whether the same individual should serve as both Chairman of the Board and CEO. This approach allows the Board to elect the most qualified Director as Chairman of the Board while also maintaining the ability to separate the Chairman of the Board and CEO roles when necessary or appropriate.
In 2018, the Board elected F. Nicholas Grasberger III, President & CEO of the Company, as Chairman of the Board. The Board intends to elect Edgar Purvis, Jr. as Independent Lead Director of the Board, effective immediately following the Annual Meeting. Mr. Purvis is replacing David C. Everitt, who has served as Independent Lead Director since 2018.
When the Board appoints a Lead Director, it reviews the Lead Director’s role and responsibilities to ensure responsible oversight, including taking into account feedback received from existing investors. The Company’s Lead Director has the following responsibilities, which are set forth in the Company’s Corporate Governance Principles:
|
• |
|
Establishing the agenda for the executive sessions of the independent Directors; |
|
• |
|
Calling meetings of the independent Directors, in addition to the executive sessions of independent Directors held after each Board meeting; |
|
• |
|
Chairing the executive sessions and other meetings of the independent Directors; |
|
|
|
12 2025 Proxy Statement |
|
|
The Board of Directors
|
• |
|
Communicating the result of meetings of the independent Directors to the Chairman and other members of management; |
|
• |
|
Regularly consulting with the Chairman; |
|
• |
|
Discussing the schedule and agenda for the Board meetings with the Chairman; |
|
• |
|
Approving the meeting schedules to assure that there is sufficient time for discussion of all agenda items; |
|
• |
|
Presiding at Board meetings in the absence of the Chairman; |
|
• |
|
Reviewing information that is sent to the Board and all critical communications to the Board; and |
|
• |
|
Being available for consultation and direct communication at the request of major stockholders. |
Finally, the Board has established three standing committees comprised entirely of independent Directors to assist with its oversight responsibilities: (1) the Audit Committee; (2) the Management Development and Compensation Committee (the “MD&C Committee”); and (3) the Governance Committee.
Experience, Skills, and Qualifications
The Governance Committee works with the full Board to determine the appropriate characteristics, skills, and experiences for the Board as a whole and its members. While the Governance Committee has not established minimum criteria for Director candidates, it has established important factors that it considers when evaluating potential candidates. These diverse factors are set forth in the Board’s Corporate Governance Principles and include integrity and strength of character, mature judgment, strategic thinking, demonstrated leadership skills, relevant business experience, experience with international business issues and risk, public company experience, innovation, technology or information technology expertise, availability, career specialization, relevant technical skills, time and willingness to perform duties as a Director, absence of conflicts of interest, and the extent to which the candidate would fill a present need on the Board. In addition, as explained in more detail below in the section entitled “Diversity,” the Board is committed to a policy of inclusiveness that requires, to the extent consistent with applicable legal requirements, that all new Board nominees be drawn from a pool that includes diverse candidates that consider the factors above.
In addition to evaluating new Director candidates, the Governance Committee regularly assesses the composition of the Board in order to ensure it reflects an appropriate balance of knowledge, skills, expertise, and independence. As part of this assessment, each Director is asked to identify and assess the particular experiences, skills, and other attributes that qualify him or her to serve as a member of the Board.
In accordance with a Cooperation Agreement between the Company and Neuberger Berman Group LLC and certain of its affiliates (“Neuberger Berman”), the Board recently nominated Nicholas C. Fanandakis as a new independent Director and anticipates appointing an additional highly qualified independent Director in the coming months. In addition, the Company expects to continue to make changes to its Board in 2026 as part of its Board refreshment program.
Set forth below is a general description of the types of experiences and skills the Governance Committee and the Board believe to be particularly relevant to the Company at this time:
Leadership Experience
Directors who have demonstrated significant leadership experience over an extended period of time, especially current and former executive officers or leaders of significant business units, provide the Company with valuable insights that can only be gained through years of managing complex organizations. These individuals understand both the day-to-day operational responsibilities facing senior management and the role Directors play in overseeing the affairs of large organizations.
International Experience
Given the Company’s global footprint and current focus on growing its presence in emerging markets, Directors with experience in markets outside the United States are critical to the Company’s long-term success.
|
|
|
|
|
2025 Proxy Statement 13 |
The Board of Directors
Industry Experience
The Company’s mission of turning the world to green requires highly specialized knowledge and expertise. Directors with experience in the environmental, industrial, and locomotive industries bring significant value to the Board.
Financial Experience
Directors with an understanding of accounting, finance, and financial reporting processes, particularly as they relate to large, multi-national businesses, are critical to the Company. Accurate financial reporting is a cornerstone of the Company’s success, and Directors with financial expertise help to provide effective oversight of the Company’s financial measures and processes.
Operational Experience
Our Directors have significant experience driving results for organizations around the world and leverage their knowledge to advance the Company’s strategic objectives.
A description of the most relevant experiences, skills, attributes, and qualifications that qualify each Director candidate to serve as a member of the Board is included in his or her biography.
Diversity
The Board believes that diversity is one of many important considerations in board composition. To ensure the Board is comprised of members with an appropriate mix of characteristics, skills, experiences, and backgrounds, the Board has adopted a Board diversity policy, which is set forth in the Board’s Corporate Governance Principles and the Governance Committee’s written charter. Pursuant to the diversity policy, and to the extent consistent with applicable legal requirements, the Board is committed to seeking out candidates with diverse backgrounds, experiences, and skills as part of each Board search the Company undertakes, and to ensuring that Board nominees are drawn from a pool that includes diverse candidates.
As noted above, the Governance Committee regularly evaluates the Board’s current composition to ensure that the Directors reflect a diverse mix of skills, experiences, backgrounds, and opinions. Depending on the current composition of the Board, the Governance Committee may weigh certain factors, including those relating to diversity (to the extent consistent with applicable legal requirements) more or less heavily when evaluating potential Director candidates.
The Board and the Governance Committee believe that the Company’s current Directors, as a group, reflect the diverse mix of skills, experiences, backgrounds, and opinions necessary to foster an effective decision-making environment and promote the Company’s culture across the globe. Each of the Company’s current Directors has significant experience working in international environments (including Directors who have lived and worked outside the United States for significant portions of their careers), and Board member experiences cover a wide range of industries, including those especially relevant to our lines of business.
Service on Other Boards
The Company’s Corporate Governance Principles provide limitations and requirements for Directors’ service on other boards of directors. Independent Directors who are members of the Audit Committee may serve on audit committees of no more than three public companies, including the Board. Non-Executive Directors may serve on the boards of directors of no more than four public companies, including the Board. The Company’s Corporate Governance Principles provide for the Board to make an exception on a case-by-case basis; however, no exceptions have been made for existing Directors. The Governance Committee reviews annually each Director’s time commitments to other companies in determining whether each Director should be nominated to the Board at an upcoming Annual Meeting.
In addition, in the event a Director is invited to serve on another for-profit company’s board of directors, such Director must provide advance notice to the Chairman of the Board and the Chair of the Governance Committee, and the Board must approve the additional time commitment on such Director before the Director may accept the invitation. In considering such approval, the Board takes into consideration the extent to which a Director’s ability to adequately fulfill his or her responsibilities to the Company and the Board may be impaired by service on other boards or committees.
|
|
|
14 2025 Proxy Statement |
|
|
Corporate Governance
We have a long-standing commitment to good corporate governance practices. These practices come in many different forms and apply at all levels of our organization. They provide the Board and our senior management with a framework that defines responsibilities, sets high standards of professional and personal conduct and promotes compliance with our various financial, ethical, legal, and other obligations and responsibilities.
Corporate Governance Principles
The Board has adopted Corporate Governance Principles that, along with the charters of the Board committees, provide the framework for our Board’s operation and governance. The Governance Committee is responsible for overseeing and reviewing our Corporate Governance Principles at least annually and recommending any proposed changes to the Board for approval. The Corporate Governance Principles are available on our website at https://www.enviri.com/corporate-governance in the Corporate Governance section.
Code of Conduct
We have adopted a Code of Conduct applicable to our Directors, officers and employees worldwide. The Code of Conduct is available in booklet form and an online training program facilitates new employee orientation and individual refresher training. Our Code of Conduct is produced in over 20 languages. The Code of Conduct, including amendments thereto or waivers thereof granted to a Director or executive officer, if any, can be viewed on our website at https://www.enviri.com/corporate-governance in the Corporate Governance section.
Stockholder and Interested Party Communications with Directors
The Board has established a formal process for stockholders and interested parties to communicate directly with the Lead Director, the non-management Directors or with any individual member of the Board. Stockholders and interested parties may contact any member of the Board by writing to the specific Board member in care of our Corporate Secretary at our Corporate Headquarters (Two Logan Square, 100-120 North 18th Street, 17th Floor, Philadelphia, PA 19103). Our Corporate Secretary will forward any such correspondence to the applicable Board member; provided, however, that any such correspondence that is considered by our Corporate Secretary to be improper for submission to the intended recipients will not be provided to such Directors. In addition, Board members, including the Lead Director, can be contacted by e-mail at BoardofDirectors@enviri.com.
Director Independence
The Board has affirmatively determined that the following eight Directors are independent pursuant to the applicable independence requirements set forth in the NYSE Rules and by the SEC because they either have no relationship with the Company (other than as a Director and stockholder) or because any relationship they have with the Company is immaterial: Messrs. Earl, Everitt, Laurion, Purvis, Quinn and Widman, and Mses. Haznedar and O’Mara. In addition, the Board has affirmatively determined that Nicholas C. Fanandakis, a Director nominee, is also independent. In making these independence determinations, the Board, in consultation with the Governance Committee, reviewed the direct and indirect relationships between each Director and Director nominee and the Company and its subsidiaries, as well as the compensation and other payments each Director and Director nominee received from or made to the Company and its subsidiaries.
Nominations of Directors
The Governance Committee is responsible for overseeing the selection of qualified nominees to serve as members of the Board. Consistent with the Board diversity policy, in administering its oversight responsibilities, the Governance Committee is committed to seeking out candidates with diverse backgrounds, experiences and skills as part of each Board search the Company undertakes, and to ensuring that Board nominees are drawn from a pool that includes diverse candidates, to the extent consistent with applicable legal requirements.
Beyond those specific parameters, the Governance Committee has not adopted formal selection procedures, but instead utilizes general guidelines that allow it to adjust the selection process to best satisfy the objectives established for any Director search. The Governance Committee considers Director candidates recommended by any reasonable source, including current Directors, management and stockholders.
|
|
|
26 2025 Proxy Statement |
|
|
Discussion and Analysis of 2024 Compensation
With respect to setting compensation levels for the other NEOs, the MD&C Committee strives to deliver a competitive level of total compensation to each of the NEOs by evaluating and balancing the following objectives:
|
|
Factors While Evaluating NEO Compensation |
|
• The strategic importance of the position within our executive team; |
|
• The overall performance level of the individual and the potential to make significant contributions to the Company in the future; |
|
• The value of the position in the marketplace; |
|
• Internal pay equity; and |
|
• Our executive compensation structure and guiding principles. |
Target total direct compensation for our NEOs, excluding the Chairman, President & CEO, is designed to deliver approximately 29% of the annual compensation opportunity in the form of base salary (fixed compensation) and approximately 71% of the annual compensation opportunity in the form of variable compensation at target performance. The amounts of compensation realized by our NEOs will vary from the target awards based upon performance evaluated under the terms of our variable compensation plans.
Each year, the Chairman, President & CEO presents his Enviri talent review to the MD&C Committee to discuss the individual performance and potential of each of the NEOs. The Chairman, President & CEO submits compensation recommendations to the MD&C Committee for each NEO. These recommendations address all elements of compensation, including base salary, target annual incentive compensation, long-term equity-based compensation, perquisites, and other benefits. In evaluating these compensation recommendations, the MD&C Committee considers information such as the NEOs’ individual performance, the performance of the Company, and the compensation of similarly situated executive officers as determined by the referenced benchmark data. The MD&C Committee applies the same considerations as noted above when making its compensation decisions for the Chairman, President & CEO.
2024 Compensation Decisions Details
Base Salary
Base salary represents a stable source of income (fixed compensation) and is a standard element of compensation necessary to attract and retain talent. Base salary is set at the MD&C Committee’s discretion after taking into account the competitive landscape including the compensation practices of the companies in our selected Compensation Peer Group and survey data from a broader index of comparable companies, our business strategy, our short- and long-term performance goals, and individual factors, such as position, salary history, individual performance and contribution, an individual’s length of service with the Company, and placement within the general base salary range offered to our NEOs.
During 2024, the MD&C Committee approved merit-based salary increases for eligible NEOs to become effective January 1, 2024. The MD&C Committee recommended, and the Board approved maintaining Mr. Grasberger’s base salary at his 2023 level. Ms. Kozak’s and Mr. Beswick’s increases of 4% were merit-based consistent with the overall timing and budget for all merit-based salary increases for Enviri employees in the United States. Mr. Hochman’s increase of 5% was merit-based and further adjusted to bring his salary to a more competitive market level for his experience and role. Since Mr. Vadaketh was appointed late 2023 to his role, no merit-based increase was awarded.
Consistent with this process, early in 2025, the MD&C Committee also approved merit-based salary increases, which became effective January 1, 2025, for our NEOs other than Mr. Grasberger, while the MD&C Committee recommended, and the Board approved, maintaining Mr. Grasberger’s base salary at its 2024 level, all as shown in the table below. Mr. Hochman and Ms. Kozak received merit-based increases of 3.5%, which were consistent with the overall timing and budget for all merit-based salary increases for Enviri employees in the United States. Messrs. Vadaketh and Beswick’s increases were merit-based and further adjusted to bring their salaries to a more competitive market level for their experience and role.
|
|
|
50 2025 Proxy Statement |
|
|
Discussion and Analysis of 2024 Compensation
Stock Ownership Guidelines
In 2024, we continued to maintain stock ownership guidelines that applied to the NEOs. Our stock ownership guidelines encourage the retention of stock acquired through our LTIP awards. No shares may be sold by participants until their applicable ownership guidelines are satisfied, subject to a hardship exception administered by the MD&C Committee.
The stock ownership guidelines are established as a multiple of each NEO’s base salary and were benchmarked against the stock ownership guidelines for similarly situated executives at Peer Group companies. They were also based on the Board’s determination of appropriate share ownership levels based on our compensation system. Under the guidelines, each NEO is encouraged to own a specific amount of our common stock and is restricted from selling shares until the guideline has been satisfied. The share ownership levels, based on fair market value as measured periodically, for each NEO for 2024 were as follows:
|
|
|
|
|
Name |
|
Level |
|
|
F. Nicholas Grasberger III |
|
|
|
|
Tom G. Vadaketh |
|
|
|
|
Russell C. Hochman |
|
|
|
|
Jeffrey A. Beswick |
|
|
|
|
Jennifer O. Kozak |
|
|
Our NEOs have five years from the date they are first granted LTIP awards to comply with the guidelines. If a NEO is promoted into a position with greater ownership requirements, that individual has five additional years to comply with the new guideline. All common stock held by the NEOs, whether acquired because of an LTIP award or otherwise, is included in determining whether they have achieved the applicable ownership guideline. Unvested stock options, unvested PSUs, and unvested SARs are not included in calculating whether the guidelines have been met. Failure to meet the guidelines within the applicable five-year period, will result in a review by the MD&C Committee to determine the cause of such failure and to develop an appropriate corrective action plan.
Mr. Grasberger, Mr. Vadaketh and Mr. Hochman previously met their ownership guidelines. As of December 31, 2024, Mr. Beswick and Ms. Kozak are within the five-year phase-in period for meeting their ownership guidelines and continue to accumulate shares.
Right to Recover Incentive Compensation
Consistent with the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”), and the NYSE Listed Company Manual, the Board has adopted a policy providing for the Company to recover (or “claw back”) from certain current and former key employees any wrongfully earned performance-based compensation, including stock-based awards, if the Company is required to prepare an accounting restatement of any of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under U.S. securities laws, subject to certain limited exceptions permitted by applicable law or listing standards. Such claw back may be implemented by a number of available methods, as set forth in the Company’s policy and as determined by the MD&C Committee.
These provisions are designed to deter and prevent detrimental behavior and to protect our investors from financial misconduct.
Policies on Insider Trading, Hedging and Pledging of Shares
Consistent with the Dodd-Frank Act, the Company’s Insider Trading Policy prohibits all Board Directors and employees, including corporate officers, from engaging in any transaction in which they may profit from short-term speculative swings in the value of the Company securities (or “hedging”). For this purpose, “hedging” includes “short-sales” (selling borrowed securities which the seller hopes can be purchased at a lower price in the future) or “short sales against the box” (selling owned, but not delivered securities), “put” and “call” options (publicly available rights to sell or buy securities within a certain period of time at a specified price or the like), and other hedging transactions designed to minimize the risk inherent in owning common stock, such as zero-cost collars and forward sales contracts.
|
|
|
|
|
2025 Proxy Statement 61 |
Discussion and Analysis of 2024 Compensation
Our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable NYSE listing standards, and expressly prohibits Directors and employees from purchasing or selling our securities while in possession of material, non-public information, or otherwise using such information for their personal benefit.
Additionally, Board members and executives are prohibited from pledging shares as collateral for a loan or in a margin account.
Policy Regarding Tax and Accounting Impact on Executive Compensation
The MD&C Committee annually reviews and considers the deductibility of the compensation paid to our executive officers, which includes each of the NEOs. Under the Tax Cuts and Jobs Act of 2017, the exemption for qualifying performance-based compensation was repealed for taxable years beginning after December 31, 2017. As a result, compensation paid to our executive officers (on or after January 1, 2018) in excess of $1 million is generally not deductible unless it qualifies for certain transition relief. While the Company will monitor guidance and developments in this area, the MD&C Committee believes that its primary responsibility is to provide a compensation program that attracts, retains, and rewards the executive talent necessary for our success. Consequently, the MD&C Committee may pay or provide compensation that is not tax deductible or is otherwise limited as to tax deductibility.
Compensation Policies and Practices as They Relate to Risk Management
In 2024, Pearl Meyer and senior management reviewed our compensation policies and practices for all employees. They concluded, and the MD&C Committee concurred, that any risks arising from our compensation policies and practices are not reasonably likely to have a material adverse impact on the Company. In addition, we reviewed the relationship between our risk management policies and practices and the incentive compensation we provide to our NEOs and other key employees to confirm that our incentive compensation does not encourage unnecessary and excessive risk taking. The findings of these reviews indicated that:
• |
|
Our compensation program provides a balance between our short-term and long-term goals and objectives; |
• |
|
Under our compensation program, the highest amount of compensation can be achieved through consistent superior performance over sustained periods of time, which discourages short-term risk taking; |
• |
|
Incentive awards are capped by the MD&C Committee; and |
• |
|
Stock ownership guidelines, the clawback policy, and prohibition on hedging mitigate excessive risk taking. |
Furthermore, as described above, compensation decisions may include the subjective use of negative discretion, which has the ability to restrain the influence of formulae or objective factors on excessive risk taking.
Compensation Committee Report
The MD&C Committee has reviewed and discussed the Compensation Discussion & Analysis, set forth above, with management. Based on this review and discussion, the MD&C Committee recommended to the Board that the Compensation Discussion & Analysis be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Proxy Statement for our 2025 Annual Meeting of Stockholders, for filing with the SEC.
SUBMITTED BY THE MANAGEMENT DEVELOPMENT AND COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS:
E. M. Purvis, Chair
D. C. Everitt
J. F. Earl
R. M. O’Mara
J. S. Quinn
The foregoing report shall not be deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A promulgated by the SEC or Section 18 of the Exchange Act.
|
|
|
62 2025 Proxy Statement |
|
|
Discussion and Analysis of 2024 Compensation
CEO Pay Ratio Disclosure
Pursuant to Section 953(b) of the Dodd-Frank Act, the SEC issued the “Pay Ratio” disclosure rule under Item 402(u) of Regulation S-K requiring companies to disclose the ratio of annual total compensation for their Principal Executive Officer (“PEO”) to that of the employee identified as the Company’s median compensated individual.
We determined that the 2024 annual total compensation of the individual identified as the Company’s median compensated individual (excluding the CEO) was $55,808, the annual total compensation of Mr. Grasberger was $6,266,045 and the ratio between the two was 112:1.
This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described below. Because the SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.
Methodology for Selecting the Median Employee
During 2024, and consistent with SEC requirements, the Company completed a recalculation to determine its median employee for 2024 to take into account business divestiture activities that occurred in the United States.
We selected October 1, 2024 as our determination date and used foreign exchange rates effective on September 30, 2024. We applied the five percent (5%) “de minimis” allowance to exclude the following country from our employee population totaling 4.86%:
• |
|
Egypt: 579 employees or 4.86% of 11,908 |
The total population used for the “de minimis” exception prior to these exclusions is 11,908, with 3,793 being U.S. based employees, and 8,115 being non-U.S. employees. After applying the five percent (5%) “de minimis” exclusion, the total population is 11,329.
In selecting the median employee, we utilized a valid statistical sampling approach to identify a cluster of employees within 10% of the median, using a consistently applied compensation measure of annual base pay. To determine annual base pay for our hourly and our part-time employee population, we used reasonable assumptions to calculate the actual hours worked. From the cluster of employees at or near the median, we selected a median employee that best represented our overall employee population.
Putting the Ratio in Context
As discussed in the CD&A of this proxy, we target pay and benefits at competitive levels based on the job duties and location of the employee. It is our philosophy to offer total remuneration opportunities that actively support recruiting, motivating, and retaining talented employees at all levels within our organization.
Our workforce is global – we have employees located in over 30 countries around the world. Our international employee footprint is driven by the needs of our clients, with the majority of our employees working at client sites outside of the United States. As such, when interpreting our pay ratio results, it is important to keep in mind that pay practices vary by country based on client contract terms, local statutory requirements, cost of living and applicable local market competitive pay practices.
Lastly, total compensation for our Senior Executives is comprised of a significant portion that varies based on financial and stock price performance of the Company. Eighty-two percent (82%) of our CEO’s total pay varies with performance while the majority of pay for our median employee seventy-four percent (74%) is fixed base salary and overtime. The equity portion of the CEO’s pay used in the pay ratio calculation reflects his “opportunity” and the actual value of these awards will vary based on stock price and performance.
|
|
|
70 2025 Proxy Statement |
|
|
Proposal 4: Approval of Amendment No. 5 to
the 2013 Equity and Incentive Compensation Plan
On February 11, 2025, upon the recommendation of the MD&C Committee, the Board adopted Amendment No. 5 to the Company’s 2013 Equity and Incentive Compensation Plan (the “2013 Plan”) subject to stockholder approval of certain provisions of the amendment solicited by this proxy statement. The amendment is set forth in Appendix A hereto.
We are seeking stockholder approval to amend the 2013 Plan to (i) increase the number of shares of Common Stock of the Company (the “Shares”) reserved for issuance under the 2013 Plan by an additional 1,400,000 Shares, increasing the total number of Shares under the 2013 Plan from 13,677,000 to 15,077,000, with a corresponding increase in the total number of shares that may be issued or transferred upon the exercise of incentive stock options from 13,677,000 to 15,077,000 and (ii) increase the total number of Shares issuable in connection with “full value awards” (awards other than stock options, SARs or other awards for which the holder pays the intrinsic value existing as of the date of grant) from 9,688,000 Shares to 10,725,000 Shares (an increase of 1,037,000). We are also amending the 2013 Plan to clarify that all equity awards are subject to a minimum one-year vesting period, with limited exceptions. Our continuing ability to offer equity incentive awards under the 2013 Plan is critical to our ability to attract, motivate and retain qualified personnel, particularly in light of the highly competitive market for employee talent in which we operate.
The Board has determined that it is in the best interests of the Company and its stockholders to approve this proposal. The Board has approved the amendment to the 2013 Plan and share increase subject to stockholder approval and recommends that stockholders vote in favor of this proposal at the Annual Meeting. Stockholder approval of this proposal requires the affirmative vote of a majority of the outstanding Shares that are present in person or by proxy and entitled to vote on the proposal at the Annual Meeting.
If stockholders approve this proposal, Amendment No. 5 to the 2013 Plan and the share increase will become effective as of the date of stockholder approval. If stockholders do not approve this proposal, Amendment No. 5 to the 2013 Plan and share increase will not take effect and our 2013 Plan will continue to be administered in its current form. The remainder of this discussion, when referring to the 2013 Plan, refers to the 2013 Plan as if this proposal to amend the 2013 Plan is approved by our stockholders, unless otherwise specified or the context otherwise references the 2013 Plan prior to amendment.
Background
The 2013 Plan was initially adopted by the Board on March 18, 2013, and our stockholders approved it in April 2013. Subsequently, Amendment No. 1 to the 2013 Plan was adopted by the Board on February 16, 2017, and our stockholders approved it in April 2017. Subsequently, Amendment No. 2 to the 2013 Plan was adopted by the Board on February 20, 2019, and our stockholders approved it in April 2020. Subsequently, Amendment No. 3 to the 2013 Plan was adopted by the Board on February 25, 2023, and our stockholders approved it in April 2023. Subsequently, Amendment No. 4 to the 2013 Plan was adopted by the Board on February 10, 2024, and our stockholders approved it in April 2024.
As of December 31, 2024, approximately 2,946,584 Shares remained available for grant under the 2013 Plan, of which 2,091,318 were issuable as “full value awards” under the remaining 2013 Plan limitation. In connection with their review and approval of Amendment No. 5, the MD&C Committee and the Board reviewed updated data concerning the 2013 Plan as of February 11, 2025. As of that date, approximately 3,296,740 Shares remained available for grant under the 2013 Plan, of which 2,441,474 were issuable as “full value awards” under the remaining 2013 Plan limitation. The Board believes that the additional Shares to be added by Amendment No. 5, as well as the additional increase in the limitation on “full value awards,” are necessary to meet the Company’s anticipated equity compensation needs. This estimate, similar to the estimates made in connection with Amendment No. 4, is based on a forecast that takes into account our anticipated rate of growth in hiring, an estimated range of our stock price over time, our historical burn rates, and our current mix of award types under the 2013 Plan, as well as the number of Shares we have currently available for grant under our 2013 Plan. We have also considered proxy advisory firm guidelines in determining an appropriate number of Shares to request in Amendment No. 5 to the 2013 Plan.
|
|
|
|
|
2025 Proxy Statement 85 |
Proposal 4: Approval of Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
more of our officers, agents or advisors, administrative duties or powers, and may authorize one or more officers to do one or both of the following (subject to certain limitations described in the 2013 Plan):
• |
|
designate employees to receive awards under the 2013 Plan; and |
• |
|
determine the size of any such awards. |
Reasonable 2013 Plan Limits. Subject to adjustment as described in the 2013 Plan, total awards under the 2013 Plan are limited to 15,077,000 shares. In addition, the 2013 Plan contains a 71% full-value award limit, which means that, subject to adjustment as described in the 2013 Plan, the aggregate number of shares actually issued or transferred by us in connection with “full value awards” (awards other than stock options, SARs or other awards for which the holder pays the intrinsic value existing as of the date of grant) will not exceed 10,725,000 Shares (an increase of 1,037,000). However, all 15,077,000 shares available for awards under the 2013 Plan may be used for stock options and SARs. These shares may be shares of original issuance or treasury shares or a combination of the foregoing.
The 2013 Plan also provides that, subject to adjustment as described in the 2013 Plan:
• |
|
the aggregate number of shares of common stock actually issued or transferred upon the exercise of incentive stock options, or ISOs, will not exceed 15,077,000 shares of common stock; |
• |
|
no participant will be granted stock options or SARs, in the aggregate, for more than 1,000,000 shares of common stock during any calendar year; |
• |
|
no participant will be granted awards of restricted stock, RSUs, performance shares or other stock-based awards, in the aggregate, for more than 500,000 shares of common stock during any calendar year; |
• |
|
no participant in any calendar year will receive an award of performance units or other awards payable in cash, other than cash incentive awards, having an aggregate maximum value in excess of $3,000,000; |
• |
|
no participant in any calendar year will receive a cash incentive award having an aggregate maximum value in excess of $3,000,000; and |
• |
|
awards that do not comply with the minimum one-year vesting period provided for in the 2013 Plan (as further described below) will not result in the issuance or transfer of more than 5% of the maximum number of shares of common stock available under the 2013 Plan. |
Allowances for Conversion Awards and Assumed Plans. Common stock covered by awards granted under the 2013 Plan will not be counted as used unless and until the shares are actually issued or transferred. However, common stock issued or transferred under awards granted under the 2013 Plan in substitution for or in conversion of, or in connection with an assumption of, stock options, SARs, restricted stock, RSUs or other stock or stock-based awards held by awardees of an entity engaging in a corporate acquisition or merger transaction with us or any of our subsidiaries will not count against the aggregate share limit or other 2013 Plan limits described above. Additionally, shares available under certain plans that we or our subsidiaries may assume in connection with corporate transactions from another entity may be available for certain awards under the 2013 Plan under circumstances further described in the 2013 Plan, but will not count against the aggregate share limit or other 2013 Plan limits described above.
Limited Share Recycling Provisions. Common stock covered by awards granted under the 2013 Plan will not be counted as used unless and until the shares are actually issued or transferred. The 2013 Plan also provides that if any common stock issued or transferred with respect to awards granted under the 2013 Plan is forfeited, or if awards granted under the 2013 Plan expire or are settled for cash, those shares will again be available under the 2013 Plan to the extent of the forfeiture, expiration, or cash settlement. The following shares of common stock will not be added back to the aggregate share limit under the 2013 Plan: (1) shares tendered or withheld in payment of an option’s exercise price; (2) shares withheld by us to satisfy tax withholding obligations; and (3) shares that are repurchased by us with stock option proceeds. Further, all shares of common stock covered by SARs that are exercised and settled in stock, whether or not all shares of common stock covered by the SARs are actually issued to the participant upon exercise, will be considered issued or transferred pursuant to the 2013 Plan.
Minimum Vesting Periods. The 2013 Plan provides that all equity awards shall be subject to a minimum one-year vesting period, except for (1) awards up to an aggregate of 5% of the maximum number of shares common stock issued or transferred under the 2013 Plan, and (2) in the case of acceleration due to death, disability, retirement, or a change in control.
|
|
|
|
|
2025 Proxy Statement 89 |
Proposal 4: Approval of Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
No stock option may vest or be exercisable sooner than the first anniversary of the date of the grant, provided, however, that a grant of stock options may provide for the earlier vesting or exercise of such stock options in the event of the retirement, death or disability of the participant or a double-trigger change of control. Any grant of stock options may specify management objectives (as described below) that must be achieved as a condition to exercising such rights. Stock options granted pursuant to the 2013 Plan may not provide for any dividends or dividend equivalents thereon.
Stock Appreciation Rights (“SARs”). A SAR is a right, exercisable by the surrender of a related stock option (if granted in tandem with stock options) or by itself (if granted as a free- standing SAR), to receive from us an amount equal to 100%, or such lesser percentage as the MD&C Committee may determine, of the spread between the base price (or option exercise price if a tandem SAR) and the value of our shares of common stock on the date of exercise. Any grant may specify that the amount payable on exercise of a SAR may be paid by us in cash, in shares of common stock, or in any combination of the two. No SARs will be granted with an exercise or base price less than the fair market value of our common stock on the date of the grant.
SARs will be evidenced by an award agreement containing such terms and provisions, consistent with the 2013 Plan, as the MD&C Committee may approve. Any grant of a tandem SAR will provide that it may be exercised only at a time when the related stock option is also exercisable, at a time when the spread is positive, and by surrender of the related stock option for cancellation. Successive grants of a tandem SAR may be made to the same participant regardless of whether any tandem SARs previously granted to the participant remain unexercised. Each grant will specify in respect of each free-standing SAR a base price that may not be less than the market value per share of common stock on the date of grant.
Successive grants may be made to the same participant regardless of whether any free-standing SARs previously granted to the participant remain unexercised. No free-standing SAR granted under the 2013 Plan may be exercised more than ten years from the date of grant. Each grant will specify the period of continuous service with us or any subsidiary that is necessary before the SARs become exercisable. See “2013 Plan Highlights – Minimum Vesting Periods.”
No SAR may vest or be exercisable sooner than the first anniversary of the date of the grant, provided, however, that a grant of SARs may provide for the earlier vesting or exercise of such SARs in the event of the retirement, death or disability of the participant or a double-trigger change of control. Any grant of SARs may specify management objectives (as described below) that must be achieved as a condition to exercising such SARs. SARs granted pursuant to the 2013 Plan may not provide for any dividends or dividend equivalents thereon.
The MD&C Committee may grant some awards, including restricted stock, that are not subject to the minimum time-based or performance-based vesting requirements, so long as the aggregate number of shares issued or transferred under such awards does not exceed 5% of the maximum number of shares of common stock available under the 2013 Plan.
Restricted Stock. A grant of restricted stock involves the immediate transfer by us to a participant of ownership of a specific number of shares of common stock in consideration of the performance of services. The participant is entitled immediately to voting, dividend and other ownership rights in such shares of common stock. The transfer may be made without additional consideration or in consideration of a payment by the participant that is less than current market value at the date of grant, as the MD&C Committee may determine.
Restricted stock that vests upon the passage of time must be subject to a “substantial risk of forfeiture” within the meaning of Section 83 of the Internal Revenue Code for a period no shorter than one year, except that the restrictions may be removed ratably during the three-year period as the MD&C Committee may determine. Each such grant or sale of restricted stock will provide that during or after the period for which such substantial risk of forfeiture is to continue, the transferability of the restricted stock will be prohibited or restricted in the manner and to the extent prescribed by the MD&C Committee at the date of grant (which restrictions may include, without limitation, rights of repurchase or first refusal or provisions subjecting the restricted stock to a continuing substantial risk of forfeiture in the hands of any transferee). The MD&C Committee may provide in certain situations for a shorter period during which the forfeiture provisions are to apply in the event of the retirement, death or disability of the grantee or a double-trigger change of control.
Any grant of restricted stock may specify management objectives that, if achieved, will result in early termination of the restrictions applicable to such shares. If the grant of restricted stock provides that management objectives must be achieved to result in a lapse of restrictions, the restrictions cannot lapse sooner than one year, but may be subject to earlier lapse or modification by virtue of the retirement, death or disability of a participant or a double-trigger change of control.
|
|
|
|
|
2025 Proxy Statement 91 |
Proposal 4: Approval of Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
Any grant of restricted stock may also specify, in respect of any applicable management objectives, a minimum acceptable level of achievement and may set forth a formula for determining the number of shares of restricted stock on which restrictions will terminate if performance is at or above the minimum level or threshold level or levels, or is at or above the target level or levels, but falls short of maximum achievement of the specified management objectives. Any such grant must specify that the MD&C Committee must determine that the applicable management objectives have been satisfied before the termination of restrictions.
The MD&C Committee may grant some awards, including restricted stock, that are not subject to the minimum time-based or performance-based vesting requirements, so long as the aggregate number of shares issued or transferred under such awards does not exceed 5% of the maximum number of shares of common stock available under the 2013 Plan.
Any grant or sale of restricted stock may require that any or all dividends or other distributions paid with respect to the restricted stock during the period of restriction be automatically deferred and reinvested in additional shares of restricted stock, which may be subject to the same restrictions as the underlying award. However, dividends or other distributions on restricted stock with restrictions that lapse as a result of the achievement of management objectives will be deferred until and paid contingent upon the achievement of the applicable management objectives. Dividends and dividend equivalents may not be paid out on any unvested Restricted Stock awards.
Restricted Stock Units (“RSUs”). A grant of RSUs constitutes an agreement by us to deliver shares of common stock or cash to the participant in the future in consideration of the performance of services, but subject to the fulfilment of such conditions during the restriction period as the MD&C Committee may specify. During the applicable restriction period, the participant will have no rights of ownership in the common stock deliverable upon payment of the RSUs and will have no right to vote the common stock. The MD&C Committee may, at the date of grant, authorize the payment of dividend equivalents on RSUs on either a current, deferred or contingent basis, either in cash or in additional shares of common stock. However, dividends or other distributions on shares of common stock underlying RSUs with restrictions that lapse as a result of the achievement of management objectives will be deferred until and paid contingently upon the achievement of the applicable management objectives.
RSUs with a restriction period that lapses only by the passage of time will have a restriction period of at least one year, except that the restriction period may expire ratably during the three-year period as determined by the MD&C Committee. Additionally, the MD&C Committee may provide in certain situations for a shorter restriction period in the event of the retirement, death or disability of the grantee, or a double-trigger change of control. Any grant of RSUs may specify management objectives that, if achieved, will result in termination or early termination of the restriction period applicable to such shares of common stock. If the RSUs have a restriction period that lapses only upon the achievement of management objectives, the restriction period cannot lapse sooner than one year, but may be subject to earlier lapse or modification by virtue of the retirement, death or disability of the grantee or a double-trigger change of control.
The MD&C Committee may grant some awards, including RSUs, that are not subject to the minimum time-based or performance-based vesting requirements, so long as the aggregate number of shares issued or transferred under such awards does not exceed 5% of the maximum number of shares of common stock available under the 2013 Plan.
RSUs will be evidenced by an award agreement containing such terms and provisions, consistent with the 2013 Plan, as the MD&C Committee may approve. Each grant or sale of RSUs may be made without additional consideration or in consideration of a payment by such participant that is less than the market value per share of common stock at the date of grant. Each grant or sale of RSUs will also specify the time and manner of payment of the RSUs that have been earned and will specify that the amount payable with respect to such grant will be paid by us in shares of common stock or cash, or a combination of the two.
Any grant of RSUs may also specify, in respect of any applicable management objectives, a minimum acceptable level of achievement and may set forth a formula for determining the number RSUs for which the restriction period will terminate if performance is at or above the minimum or threshold level or levels, or is at or above the target level or levels, but falls short of maximum achievement of the specified management objectives. Any such grant must specify that the MD&C Committee must determine that the applicable management objectives have been satisfied before the termination of restrictions. Dividends and dividend equivalents may not be paid out on any unvested Restricted Stock Unit awards.
|
|
|
92 2025 Proxy Statement |
|
|
Proposal 4: Approval of Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
Cash Incentive Awards, Performance Shares and Performance Units. A cash incentive award is a cash award based on the achievement of management objectives. A performance share is the equivalent of one share of common stock and a performance unit is the equivalent of $1.00 or such other value as determined by the MD&C Committee. A participant may be granted any number of cash incentive awards, performance shares or performance units, subject to the limitations set forth above. The participant will be given one or more management objectives to meet within a specified period, or Performance Period. The specified Performance Period will be a period of time not less than one year, with limited exceptions in the case of the retirement, death or disability of the grantee, or a double-trigger change of control, if the MD&C Committee so determines.
The MD&C Committee may, however, grant some awards, including performance shares, that are not subject to these minimum vesting requirements, so long as the aggregate number of shares issued or transferred under such awards does not exceed 5% of the maximum number of shares of common stock available under the 2013 Plan. Dividends and dividend equivalents may not be paid out on any unvested Performance Shares and Performance Share unit awards.
Each grant of cash incentive awards, performance shares or performance units may specify, in respect of the relevant management objectives, a minimum acceptable level or levels of achievement and will set forth a formula for determining the number of performance shares or performance units, or amount payable with respect to cash incentive awards, that will be earned if performance is at or above the minimum or threshold level or levels, or is at or above the target level or levels, but falls short of maximum achievement of the specified management objectives. Any such grant must specify that the MD&C Committee must determine that the applicable management objectives have been satisfied before the payment of the award.
To the extent earned, the cash incentive awards, performance shares or performance units will be paid to the participant at the time and in the manner determined by the MD&C Committee. Any grant may specify that the amount payable with respect thereto may be paid by us in cash, shares of common stock, in restricted stock or restricted stock units, or any combination thereof. The MD&C Committee may, at the date of grant of performance shares, provide for the payment of dividend equivalents to a participant either in cash or in additional shares of common stock, subject in all cases to deferral and payment on a contingent basis based on the participant’s earning of the performance shares with respect to which such dividend equivalents are paid.
Cash incentive awards, performance shares and performance units will be evidenced by an award agreement containing such terms and provisions, consistent with the 2013 Plan, as the MD&C Committee may approve. Each grant will specify the amount of cash incentive awards, performance shares or performance units to which it pertains, which number may be subject to adjustment to reflect changes in compensation or other factors.
Other Awards. The MD&C Committee may, subject to limitations under applicable law, grant to any participant such other awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, shares of common stock or factors that may influence the value of such shares, including, without limitation:
• |
|
convertible or exchangeable debt securities; |
• |
|
purchase rights for shares of common stock; |
• |
|
awards with value and payment contingent upon our performance or specified subsidiaries, affiliates or other business units of ours or any other factors designated by the MD&C Committee; and |
• |
|
awards valued by reference to the book value of shares of common stock or the value of securities of, or the performance of specified subsidiaries or affiliates or other business units of ours. |
The MD&C Committee will determine the terms and conditions of the other awards. Shares of common stock delivered pursuant to an award in the nature of a purchase right will be purchased for such consideration, paid for at such time, by such methods, and in such forms, including, without limitation, shares of common stock, other awards, notes or other property, as the MD&C Committee will determine. Cash awards, as an element of or supplement to any other award granted under the 2013 Plan, may also be granted.
Regardless of whether the earning or vesting of, or elimination of restrictions applicable to, awards granted under this section of the 2013 Plan is based on the passage of time or the achievement of management objectives, the earning, vesting or restriction period may not terminate sooner than one year from the date of the grant. Notwithstanding the foregoing, any grant of an award under this section of the 2013 Plan may provide for the earning or vesting of, or earlier elimination of restrictions applicable to, such award in certain circumstances in the event of the retirement, death, or disability of the participant, or a double-trigger change of control.
|
|
|
|
|
2025 Proxy Statement 93 |
Proposal 4: Approval of Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
• |
|
any cash incentive awards, performance shares or performance units which have not been fully earned; |
• |
|
any other awards subject to any vesting schedule or transfer restriction; or |
• |
|
shares of common stock subject to any transfer restriction imposed by the 2013 Plan; |
the MD&C Committee may, in its sole discretion (other than in the event of a change in control), accelerate the time at which:
• |
|
such stock option or SAR or other award may be exercised; |
• |
|
such substantial risk of forfeiture or prohibition or restriction on transfer will lapse; |
• |
|
such restriction period will end; or |
• |
|
such cash incentive awards, performance shares or performance units will be deemed to have been fully earned or the time when such transfer restriction will terminate. |
The MD&C Committee may also waive any other limitation or requirement under any such award, other than a limitation or requirement that is mandatory under the 2013 Plan.
The MD&C Committee may amend the terms of any awards granted under the 2013 Plan prospectively or retroactively. Except in connection with certain corporate transactions described in the 2013 Plan, no amendment will materially impair the rights of any participant without his or her consent.
Our Board may, in its discretion, terminate the 2013 Plan at any time. Termination of the 2013 Plan will not affect the rights of participants or their successors under any outstanding awards and not exercised in full on the date of termination.
In addition to the provisions in the 2013 Plan regarding acceleration of awards, up to 5% of the maximum number of shares of common stock that may be issued or transferred under the 2013 Plan, as may be adjusted, may be used for stock options, SARs, restricted stock, RSUs, performance shares, performance units and other awards granted under the 2013 Plan that do not comply with the applicable one-year vesting requirements with respect to time-vested awards or awards subject to the achievement of performance goals.
No Repricing of Stock Options or SARs. Except in connection with certain corporate transactions described in the 2013 Plan, the terms of outstanding awards may not be amended to reduce the option price of outstanding stock options or the base price of outstanding SARs, or cancel outstanding stock options or SARs that have an exercise price or base price in excess of the current market price of the underlying shares in exchange for cash, other awards or stock options or SARs with an option price or base price, as applicable, that is less than the option price of the original stock options or base price of the original SARs, as applicable, without stockholder approval. This restriction is intended to prohibit the repricing of “underwater” stock options and SARs and will not be construed to prohibit the adjustments in connection with certain corporate transactions provided for in the 2013 Plan. This prohibition may not be amended without approval by our stockholders.
Transferability. Except as otherwise determined by the MD&C Committee (subject to applicable limitations under tax laws), no stock option, SAR, restricted stock, RSU, performance share, performance unit, cash incentive award or other awards granted under the 2013 Plan, or dividend equivalents paid with respect to awards made under the 2013 Plan, will be transferable by the participant except by will or the laws of descent and distribution, and in no event shall any such award granted under the 2013 Plan be transferred for value. Except as otherwise determined by the MD&C Committee, stock options and SARs will be exercisable during the participant’s lifetime only by him or her or, in the event of the participant’s legal incapacity to do so, by his or her guardian or legal representative acting on behalf of the participant in a fiduciary capacity under state law and/or court supervision.
The MD&C Committee may provide at the date of grant additional restrictions on transfer for certain shares of common stock earned under the 2013 Plan.
Adjustments. The MD&C Committee shall make or provide for such adjustments in the numbers of shares of common stock covered by outstanding stock options, SARs, RSUs, performance shares and performance units granted under the 2013 Plan and, if applicable, in the number of shares of common stock covered by other awards, in the option price and base price provided in outstanding stock options and SARs, in the kind of stock covered by such awards and in cash incentive awards as the MD&C Committee, in its sole
|
|
|
|
|
2025 Proxy Statement 95 |
Proposal 4: Approval of Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
discretion, exercised in good faith, may determine is equitably required to prevent dilution or enlargement of the rights of participants or optionees that otherwise would result from:
• |
|
any stock dividend, stock split, combination of stock, recapitalization or other change in the capital structure of our company; |
• |
|
any merger, consolidation, spin-off, split-off, spin-out, split-up, reorganization, partial or complete liquidation or other distribution of assets, extraordinary dividend of cash or property, issuance of rights or warrants to purchase securities; or |
• |
|
any other corporate transaction or event having an effect similar to these events or transactions or that otherwise constitutes an “equity restructuring” within the meaning of FASB ASC Topic 718. |
In the event of any such transaction or event or in the event of a change of control, the MD&C Committee, in its discretion, may provide in substitution for any or all outstanding awards under the 2013 Plan such alternative consideration (including cash), if any, as it, in good faith, may determine to be equitable in the circumstances and may require the surrender of all awards so replaced in a manner that complies with Section 409A of the Internal Revenue Code.
In addition, for each stock option or SAR with an option price or base price greater than the consideration offered in connection with any such termination or event or change of control, the MD&C Committee may in its sole discretion elect to cancel such stock option or SAR without any payment to the person holding such stock option or SAR. The MD&C Committee shall also make or provide for such adjustments in the total number of shares of common stock available under the 2013 Plan, the per-person award limits expressed in shares and any other share limits under the 2013 Plan as the MD&C Committee, in its sole discretion, exercised in good faith, may determine is appropriate to reflect any transaction or event described above, subject to applicable requirements under Code Sections 409A and 162(m). However, any adjustment to the number of ISOs that may be granted under the 2013 Plan will be made only if and to the extent that such adjustment would not cause any option intended to qualify as an ISO to fail to so qualify.
Detrimental Activity and Recapture Provisions. Any award agreement may provide for the cancellation or forfeiture of an award or the forfeiture and repayment of any gain related to an award, or other provisions intended to have a similar effect, upon terms and conditions determined by the MD&C Committee, if a participant, either during his or her employment by us or a subsidiary or within a specific period after termination of employment, engages in any “detrimental activity” (as defined in such award agreement). In addition, any award agreement may provide for the cancellation or forfeiture of an award or the forfeiture and repayment to us of any gain related to an award, or other provisions intended to have a similar effect, upon such terms and conditions as may be determined by the MD&C Committee from time to time or under Section 10D of the Exchange Act, or the rules of any national securities exchange or national securities association on which our common stock is traded.
Withholding Taxes. To the extent that we are required to withhold federal, state, local or foreign taxes in connection with any payment made or benefit realized by a participant or other person under the 2013 Plan, and the amounts available to us for such withholding are insufficient, it will be a condition to the receipt of such payment or the realization of such benefit that the participant or such other person make arrangements satisfactory to us for payment of the balance of such taxes required to be withheld, which arrangements (in the discretion of the MD&C Committee) may include relinquishment of a portion of such benefit or the delivery to us of our common stock. In no event shall the market value per share of the common stock to be withheld and delivered to satisfy applicable withholding taxes in connection with the benefit exceed the minimum amount of taxes required to be withheld, if necessary to avoid additional accounting expense.
Termination. No grant will be made under the 2013 Plan after April 19, 2030, but all grants made on or prior to such date will continue in effect thereafter subject to the terms of the applicable award agreement and the terms of the 2013 Plan.
Federal Income Tax Consequences
The following is a brief summary of some of the federal income tax consequences of certain transactions under the 2013 Plan based on federal income tax laws in effect. This summary, which is presented for the information of stockholders considering how to vote on this proposal and not for 2013 Plan participants, is not intended to be complete and does not describe federal taxes other than income taxes (such as Medicare and Social Security taxes), state local or foreign tax consequences.
|
|
|
96 2025 Proxy Statement |
|
|
Proposal 5: Approval of Amendment No. 3 to
the 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan
On February 11, 2025, upon the recommendation of the Governance Committee, the Board adopted Amendment No. 3 to the Company’s 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan (the “2016 Directors’ Plan”) subject to stockholder approval of the amendment solicited by this proxy statement. The amendment is set forth in Appendix B hereto.
We are seeking stockholder approval to amend the 2016 Directors’ Plan to increase the number of shares of Common Stock of the Company (the “Shares”) reserved for issuance under the 2016 Directors’ Plan by an additional 400,000 Shares, increasing the total number of Shares under the 2016 Directors’ Plan from 800,000 to 1,200,000. Our continuing ability to offer equity incentive awards under the 2016 Directors’ Plan is critical to our ability to attract, motivate and retain highly-qualified persons to serve as non-employee directors, particularly in light of the highly competitive market for talent in which we operate, and to promote ownership by non-employee directors of a greater proprietary interest in the Company, thereby aligning such directors’ interests more closely with the interests of our stockholders.
The Board has determined that it is in the best interests of the Company and its stockholders to approve this proposal. The Board has approved the amendment to the 2016 Directors’ Plan and share increase subject to stockholder approval and recommends that stockholders vote in favor of this proposal at the Annual Meeting. Stockholder approval of this proposal requires the affirmative vote of a majority of the outstanding Shares that are present in person or by proxy and entitled to vote on the proposal at the Annual Meeting.
If stockholders approve this proposal, Amendment No. 3 to the 2016 Directors’ Plan and the share increase will become effective as of the date of stockholder approval. If stockholders do not approve this proposal, Amendment No. 3 to the 2016 Directors’ Plan and share increase will not take effect and our 2016 Directors’ Plan will continue to be administered in its current form. The remainder of this discussion, when referring to the 2016 Directors’ Plan, refers to the 2016 Directors’ Plan as if this proposal to amend the 2016 Directors’ Plan is approved by our stockholders, unless otherwise specified or the context otherwise references the 2016 Directors’ Plan prior to amendment.
Background
The 2016 Directors’ Plan was initially adopted by the Board effective February 19, 2016, and our stockholders approved it in April 2016. Effective July 27, 2016, the Board approved Amendment No. 1 to the 2016 Directors’ Plan, which did not require stockholder approval, to delete the ability of the Committee (as defined below) to grant awards of restricted stock to non-employee directors with vesting based on the achievement of performance goals. The initial share reserve under the 2016 Directors’ Plan was 400,000 Shares. The Board approved Amendment No. 2 to the 2016 Directors’ Plan on February 8, 2021, and effective April 20, 2021, the stockholders approved such Amendment No. 2, which increased the share reserve under the 2016 Directors’ Plan from 400,000 Shares to 800,000 Shares. As of December 31, 2024, approximately 52,971 Shares remained available for grant under the 2016 Directors’ Plan.
Reasons for Voting for the Proposal
Enviri delivers a significant portion of the compensation of its non-employee directors in the form of equity awards. We believe this approach to director compensation aligns the interests of the Company’s non-employee directors with those of its stockholders and is consistent with best practices and regulatory principles.
|
|
|
|
|
2025 Proxy Statement 99 |
Proposal 5: Approval of Amendment No. 3 to the 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan
All awards made under the 2016 Directors’ Plan are discretionary. Therefore, the benefits and amounts that will be received or allocated under the 2016 Directors’ Plan are not determinable at this time. None of the new shares being requested are needed to cover any outstanding awards. As of February 11, 2025, the fair market value of one share of our common stock was $9.24 (the closing price of our common stock on February 11, 2025).
Description of the 2016 Directors’ Plan, as Amended
The following is a description of the principal provisions of the 2016 Directors’ Plan, as amended. This summary is qualified in its entirety by reference to the full text of Amendment No. 3 attached as Appendix B to this Proxy Statement, and to the 2016 Directors’ Plan document, together with Amendment No. 1 and Amendment No. 2 thereto, which have been previously filed with the Securities and Exchange Commission and are available as Exhibit 10.45, Exhibit 10.46, and Exhibit 10.47, respectively, to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
2016 Directors’ Plan Highlights
Administration
The 2016 Directors’ Plan is administered by the Board; provided, however, that a committee of the Board may perform the functions of the Board under the 2016 Directors’ Plan to the extent authorized under such committee’s charter. In the event that a committee performs the functions of the Board, all references to the Board in this summary shall be deemed to include such committee (herein, the “Committee”). Subject to the express provisions of the 2016 Directors’ Plan, the Board has the authority, in its discretion, to interpret the 2016 Directors’ Plan, establish rules and regulations for its operation, select eligible individuals to receive awards and determine the form and amount and other terms and conditions of such awards. The Committee may amend, but not accelerate, the terms and conditions of any outstanding Award to the extent such terms and conditions are within the discretion of the Committee as provided in the 2016 Directors’ Plan.
The Company typically approves equity awards at the first regularly scheduled Governance Committee meeting of the fiscal year. The Company does not time equity grants in coordination with the release of material nonpublic information (“MNPI”). If an equity award is granted outside the regular cycle, the MD&C Committee carefully assesses whether MNPI exists and, if necessary, may delay the grant until after such information is publicly disclosed. For the 2024 equity grants, no awards were approved within four business days before or one business day after the filing of a Form 10-Q, 10-K, or 8-K disclosing MNPI.
Summary of Award Terms and Conditions
Awards under the 2016 Directors’ Plan include nonqualified stock options, stock appreciation rights, restricted shares of common stock and restricted stock units.
Stock Options. The Board may grant a participant options to purchase Company common stock that do not qualify as incentive stock options (“nonqualified stock options”). The terms and conditions of stock option grants, including the quantity, price, vesting periods, and other conditions on exercise will be determined by the Board.
The exercise price for stock options will be determined by the Board in its discretion, but may not be less than 100% of the fair market value of one share of the Company’s common stock on the date when the stock option is granted.
Stock options must be exercised within a period fixed by the Board that may not exceed ten years from the date of grant. Unless otherwise determined by the Board, each stock option will become fully exercisable one year after the date of grant; provided, however, that a stock option previously granted to a participant will be fully exercisable after the participant ceases to serve as a director of the Company due to death or disability or retirement under the Company’s then-applicable mandatory retirement policy.
Payment for shares of common stock on the exercise of stock options may be made in cash, shares of the Company’s common stock held by the participant or, at the Board’s discretion, in any other form of consideration acceptable to the Committee (including one or more forms of “cashless” or “net” exercise).
|
|
|
102 2025 Proxy Statement |
|
|
Proposal 5: Approval of Amendment No. 3 to the 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan
Stock Appreciation Rights (“SARs”). A participant may receive an award of stock appreciation rights, which entitles the participant to receive, upon its exercise, a payment equal to (i) the excess of the fair market value of a share of common stock on the exercise date over the grant price, multiplied by (ii) the number of shares of common stock with respect to which the stock appreciation right is exercised.
The grant price for a stock appreciation right will be 100% of the fair market value of one share of the Company’s common stock on the date when the stock appreciation right is granted. Stock appreciation rights must be exercised within a period fixed by the Board that may not be less than one year or exceed ten years from the date of grant. Upon exercise of a stock appreciation right, payment may be made in cash, shares of Company stock or a combination of cash and stock. No SAR may vest more rapidly than one year from the date of the grant, except in the case of death, disability or retirement.
Restricted Shares and Restricted Units. The Board may award participants shares of common stock subject to specified restrictions (“restricted shares”). All awards of restricted shares that vest based on the passage of time shall vest no more rapidly than one year from the date of grant (“time-based restricted stock”); provided, however, that up to 5% of the time-based restricted stock may be subject to a more accelerated vesting schedule.
The Board also may award participants units representing the right to receive the value of a share of common stock (“restricted units”). Settlement of vested restricted units may be made in the form of cash, shares of Company stock or a combination of cash and stock. Unless otherwise determined by the Board, if not previously forfeited, restricted units shall vest at the close of business on the first anniversary of the date of the grant of such award.
The terms and conditions of restricted share and restricted unit awards are determined by the Committee.
Eligibility and Limitation on Awards. Eligibility to participate in the 2016 Directors’ Plan is limited to non-employee directors of the Company, a group which currently includes the eight non-employee Directors who are serving and have been nominated for reelection in this proxy statement. While the selection of participants is within the discretion of the Board, it is presently contemplated that, if Amendment No. 3 to the 2016 Directors’ Plan is approved by Stockholders, the Company’s eight current non-employee Directors will be eligible to receive awards under the 2016 Directors’ Plan as amended. The maximum amount of awards that can be granted under the 2016 Directors’ Plan to a single participant in any calendar year is awards totaling $400,000.
Shares Subject to the 2016 Directors’ Plan. Subject to stockholder approval of the proposed Amendment No. 3, the total number of shares of the Company’s common stock reserved for issuance with respect to awards under the 2016 Directors’ Plan will be increased from 800,000 shares to 1,200,000 shares, which will increase the number of shares available for new awards from 52,971 remaining shares to 452,971 remaining shares.
Shares of common stock underlying awards granted under the 2016 Directors’ Plan that expire or are forfeited or terminated for any reason (with the exception of the termination of a tandem stock appreciation right upon exercise of the related stock option, or the termination of a related stock option upon exercise of the corresponding tandem stock appreciation right), as well as any shares underlying a stock appreciation right that is settled in cash rather than stock, will be available for future grants under the 2016 Directors’ Plan. In addition:
• |
|
If shares are tendered or otherwise used in payment of the option price of a stock option, the total number of shares covered by the option being exercised will reduce the number of shares available under the 2016 Directors’ Plan; |
• |
|
Shares withheld by the Company to satisfy the tax withholding obligation will reduce the number of shares available under the 2016 Directors’ Plan; and |
• |
|
The number of shares covered by a stock appreciation right, to the extent that it is exercised and settled in stock, and whether or not all shares covered by the stock appreciation right are actually issued to the participant, will be considered issued. |
If a participant has elected to give up the right to receive compensation in exchange for shares based on fair market value, such shares will not count as shares issued under the 2016 Directors’ Plan.
Anti-Dilution Protections. In the event of any change in corporate capitalization such as a stock split or stock dividend, or a corporate transaction such as any reorganization, merger, consolidation, separation, including a spin-off, or other distribution of stock or
|
|
|
|
|
2025 Proxy Statement 103 |
Proposal 5: Approval of Amendment No. 3 to the 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan
property of the Company, such adjustment shall be made in the number and class of shares which are reserved and may be delivered under the 2016 Directors’ Plan, in the number and class of and/or price of Shares subject to outstanding awards, and in any award limits as may be determined to be appropriate and equitable by the Board.
Amendment and Termination. Subject to the terms of the 2016 Directors’ Plan, the Board may alter, amend, suspend or terminate the 2016 Directors’ Plan in whole or in part; provided, however, no amendment shall, without stockholder approval, (i) materially increase the benefits accruing to participants under the 2016 Directors’ Plan; (ii) materially increase the number of securities which may be issued under the 2016 Directors’ Plan; or (iii) materially modify the requirements for participation in the 2016 Directors’ Plan.
No Repricing. Except in connection with a corporate transaction involving the Company, the terms of outstanding awards may not be amended to reduce the exercise price of outstanding stock options or stock appreciation rights, or cancel outstanding stock options or stock appreciation rights in exchange for cash, other awards or stock appreciation rights with an exercise price that is less than the exercise price of the original stock options or stock appreciation rights without stockholder approval.
Deferrals. The Committee may permit or require a participant to defer such Participant’s receipt of the payment of cash or the delivery of shares that would otherwise be due to such Participant by virtue of the exercise of an Option or SAR or the vesting, lapse or waiver of restrictions with respect to restricted shares.
Federal Income Tax Consequences
The federal income tax consequences of the issuance and exercise of awards under the 2016 Directors’ Plan are as described below. The following information is only a summary of the tax consequences of the awards, and participants should consult with their own tax advisors with respect to the tax consequences inherent in the ownership or exercise of the awards, and the ownership and disposition of any underlying securities.
Stock Options. A participant who is granted a nonqualified stock option under the 2016 Directors’ Plan will not recognize any income for federal income tax purposes on the grant of the option. Generally, on the exercise of the option, the participant will recognize taxable ordinary income equal to the excess of the fair market value of the shares on the exercise date over the option price for the shares. The Company generally will be entitled to a deduction on the date of exercise in an amount equal to the ordinary income recognized by the participant, subject to certain limits on the deductibility of compensation under the Code. Upon disposition of the shares purchased pursuant to the stock option, the participant will recognize long-term or short-term capital gain or loss, as the case may be, equal to the difference between the amount realized on such disposition and the basis for such shares, which basis includes the amount previously recognized by the participant as ordinary income.
Stock Appreciation Rights. A participant who is granted stock appreciation rights will normally not recognize any taxable income on the receipt of the award. Upon the exercise of a stock appreciation right, (i) the participant will recognize ordinary income equal to the amount received (the increase in the fair market value of one share of our stock from the date of grant of the award to the date of exercise), and (ii) the Company will be entitled to a deduction on the date of exercise in an amount equal to the ordinary income recognized by the participant, subject to certain limits on the deductibility of compensation under the Code.
Restricted Stock. A participant will not be taxed at the date of an award of restricted shares, but will be taxed at ordinary income rates on the fair market value of any restricted shares as of the date that the restrictions lapse, unless the participant, within 30 days after transfer of such restricted shares to the participant, elects under Section 83(b) of the Code to include in income the fair market value of the restricted shares as of the date of such award. The Company will be entitled to a corresponding deduction, subject to certain limits on the deductibility of compensation under the Code. Any disposition of shares after the restrictions lapse will be subject to the regular rules governing long-term and short-term capital gains and losses, with the basis for this purpose equal to the fair market value of the shares at the end of the restricted period (or on the date of the transfer of the restricted shares to the employee in connection with the original award, if the employee elects to be taxed on the fair market value upon such transfer). To the extent dividends are payable during the restricted period under the applicable award agreement, any such dividends will be taxable to the participant at ordinary income tax rates and will be deductible by the Company unless the participant has elected to be taxed on the fair market value of the restricted shares upon transfer, in which case they will thereafter be taxable to the participant as dividends and will not be deductible by the Company.
|
|
|
104 2025 Proxy Statement |
|
|
Other Matters
Householding of Proxy Materials
SEC rules concerning the delivery of annual disclosure documents allow us or your broker to send a single Notice or, if applicable, a single set of our proxy materials to any household at which two or more of our stockholders reside, if we or your broker believe that the stockholders are members of the same family, unless we have received contrary instructions from one or more of the stockholders. This practice, referred to as “householding,” benefits both you and the Company. It reduces the volume of duplicate information received at your household and helps to reduce our expenses. The rule applies to our Notices, annual reports, proxy statements and information statements.
We and some brokers “household” the Letter from our Chairman & CEO, Annual Report on Form 10-K and other proxy materials, delivering a single copy of each to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker or us that they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If at any time you no longer wish to participate in householding and would prefer to receive a separate copy of the proxy materials, including the Letter from our Chairman & CEO and Annual Report on Form 10-K, or if you are receiving multiple copies of the proxy materials and wish to receive only one, please notify your broker, if your shares are held in a brokerage account, or us, if you hold registered shares, at which time we will promptly deliver separate copies of the materials to each of the affected stockholders or discontinue the practice, according to your wishes. You can notify us by sending a written request to Enviri Corporation, Two Logan Square, 100-120 North 18th Street, 17th Floor, Philadelphia, PA 19103 or by calling (267) 857-8715. Stockholders who participate in householding will continue to have access to and utilize separate proxy voting instructions.
Stockholder Proposals and Nominations for Presentation at 2026 Annual Meeting of Stockholders
The 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) is expected to be held on April 23, 2026. If one of our stockholders wishes to submit a proposal for inclusion in our Proxy Statement and Proxy Card relating to the 2026 Annual Meeting, such proposal must be received by the Secretary of the Company at our principal executive offices located at Two Logan Square, 100-120 North 18th Street, 17th Floor, Philadelphia, PA 19103 no later than November [●], 2025 and must otherwise comply with the requirements of Rule 14a-8 of the SEC.
In order for a stockholder to nominate a candidate for election as a Director, or submit a proposal for consideration outside of the requirements of Rule 14a-8, at the 2026 Annual Meeting, the stockholder must provide written notice to the Secretary of the Company that is delivered to, or mailed and received at, the principal executive offices of the Company not earlier than the close of business on the 120th day and not later than the close of business on the 90th day prior to April 24, 2026, which is the first anniversary of the 2025 Annual Meeting (i.e., not earlier than December 25, 2025 and not later than January 24, 2026); provided, however, that in the event that the date of the 2026 Annual Meeting is more than 30 days before or more than 60 days after April 24, 2026, notice by the stockholder in order to be timely must be delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the 90th day prior to the 2026 Annual Meeting or, if the first public announcement or notice of the date of the 2026 Annual Meeting is made or given to stockholders less than 100 days prior to the date of the 2026 Annual Meeting, the close of business on the 10th day following the day on which public announcement was made or notice of the date of such meeting is mailed, whichever first occurs. The written notice must include and be accompanied with the information and materials described in the Company’s Amended and Restated Bylaws.
In order to nominate a candidate for election as a Director at the 2026 Annual Meeting, a stockholder must provide to the Secretary of the Company written notice, including the supporting information described under the heading “Corporate Governance – Nominations of Directors,” by personal delivery or mail not later than January 24, 2026. If the stockholder does not also comply with the requirements of Rule 14a-4(c) under the Exchange Act by providing notice to the Company by such date, the Company may exercise discretionary voting authority under proxies it solicits to vote in accordance with its best judgment on any such stockholder proposal.
|
|
|
110 2025 Proxy Statement |
|
|
Appendix A: Amendment No. 5 to the 2013
Equity and Incentive Compensation Plan
ENVIRI CORPORATION
2013 EQUITY AND INCENTIVE COMPENSATION PLAN
Amendment No. 5
WHEREAS, the Board of Directors and stockholders of Enviri Corporation (the “Company”) have adopted the 2013 Equity and Incentive Compensation Plan, together with Amendment No. 1 to the 2013 Equity and Incentive Compensation Plan, Amendment No. 2 to the 2013 Equity and Incentive Compensation Plan, Amendment No. 3 to the 2013 Equity and Incentive Compensation Plan and Amendment No. 4 to the 2013 Equity and Incentive Compensation Plan (the “Plan”);
WHEREAS, pursuant to Section 3(a) of the Plan, a total of 13,677,000 shares of the common stock, par value $1.25 per share, of the Company (the “Common Stock”) have been reserved for issuance under the Plan;
WHEREAS, the Company desires (i) to increase the number of shares issuable under the Plan to an aggregate of 15,077,000 shares, including shares previously issued thereunder, (ii) to increase the aggregate limit on the number of shares that may be issued or transferred in connection with awards other than stock options or appreciation rights to 10,725,000 shares, (iii) to increase the number of shares that may be issued or transferred upon the exercise of incentive stock options from 13,677,000 shares to 15,077,000 shares, (iv) to implement a minimum one-year vesting period for all awards, except for (a) 5% of the maximum number of shares of common stock issued or transferred under the Plan, or (b) in the case of acceleration due to death, disability, retirement or a change in control or material divestiture, (v) extend the termination date of the Plan, and (vi) eliminate references from tax regulations that are no longer pertinent, among other matters;.
WHEREAS, Section 18 of the Plan permits the Company to amend the Plan from time to time, subject only to certain limitations specified therein;
NOW, THEREFORE, the following amendments and modifications are hereby made a part of the Plan subject to, and effective as of the date of, the approval of stockholders of the Plan as amended at the Company’s Annual Meeting of Stockholders on April 24, 2025:
1. Section 2(i) of the Plan shall be, and hereby is, amended to change the definition of “Company” to Enviri Corporation.
2. Section 2(j) of the Plan shall be, and hereby is, deleted in its entirety.
3. Section 2(r) of the Plan shall be, and hereby is, deleted and replaced in its entirety to read as follows:
““Management Objectives” means the measurable performance objective or objectives established pursuant to this Plan for Participants who have received grants of Performance Shares, Performance Units or Cash Incentive Awards or, when so determined by the Committee, Option Rights, Appreciation Rights, Restricted Stock, Restricted Stock Units, dividend equivalents or other awards pursuant to this Plan.”
4. Section 2(t) of the Plan shall be, and hereby is, deleted and replaced in its entirety to read as follows:
““Non-Employee Director” means a person who is a “Non-Employee Director” of the Company within the meaning of Rule 16b-3 promulgated under the Exchange Act.”
5. Section 2(dd) of the Plan shall be, and hereby is, deleted in its entirety.
6. Section 3(a)(i) of the Plan shall be, and hereby is, amended such that clause (F) and the following proviso shall hereby read as follows:
“(F) in payment of dividend equivalents paid with respect to awards made under the Plan will not exceed in the aggregate 15,077,000 shares; provided, that notwithstanding anything in this Section 3, or elsewhere in this Plan, to the contrary and subject to
|
|
|
112 2025 Proxy Statement |
|
|
Appendix A: Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
adjustment as provided in Section 11 of this Plan, the aggregate number of shares of Common Stock actually issued or transferred by the Company in connection with awards other than Option Rights or Appreciation Rights granted under this Plan will not exceed 10,725,000 shares. Such shares may be shares of original issuance or treasury shares or a combination of the foregoing.”
7. Section 3(b) of the Plan shall be, and hereby is, amended to read as follows:
“Notwithstanding anything in this Section 3, or elsewhere in this Plan, to the contrary and subject to adjustment as provided in Section 11 of this Plan, the aggregate number of shares of Common Stock actually issued or transferred by the Company upon the exercise of Incentive Stock Options will not exceed 15,077,000 shares.”
8. Each of Section 3(c)(ii), Section 3(c)(iii), and Section 3(c)(iv) shall be, and hereby are, amended to remove each reference to “Qualified Performance-Based Awards.”
9. Section 3(d) of the Plan shall be, and hereby is, amended to read as follows:
“Notwithstanding anything in this Plan to the contrary, up to 5% of the maximum number of shares of Common Stock that may be issued or transferred under this Plan as provided for in Section 3(a) of this Plan, as may be adjusted under Section 11 of this Plan, may be used for awards granted under Section 6 through Section 9 of this Plan that do not comply with the one-year vesting requirements set forth in such sections of this Plan.”
10. Section 4 of the Plan shall be, and hereby is, amended to add the following Section 4(m):
“Each grant of Option Rights shall become exercisable no sooner than the first anniversary of the date of the grant.”
11. Section 5(b) of the Plan shall be, and hereby is, amended to add the following Section 5(b)(vii):
“Each grant of Appreciation Rights shall become exercisable no sooner than the first anniversary of the date of the grant.”
12. Section 6 of the Plan shall be, and hereby is, amended such that the Section shall hereby read as follows:
“Restricted Stock. The Committee may, from time to time and upon such terms and conditions as it may determine, authorize the grant or sale of Restricted Stock to Participants. Each such grant or sale may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the following provisions:
(a) Each such grant or sale will constitute an immediate transfer of the ownership of Common Stock to the Participant in consideration of the performance of services, entitling such Participant to voting, dividend and other ownership rights, but subject to the substantial risk of forfeiture and restrictions on transfer hereinafter referred to.
(b) Each such grant or sale may be made without additional consideration or in consideration of a payment by such Participant that is less than the Market Value per Share at the Date of Grant.
(c) Each such grant or sale will provide that the Restricted Stock covered by such grant or sale that vests upon the passage of time will be subject to a “substantial risk of forfeiture” within the meaning of Section 83 of the Code for a period to be determined by the Committee at the Date of Grant or upon achievement of Management Objectives referred to in subparagraph (e) below. If the elimination of restrictions is based only on the passage of time rather than the achievement of Management Objectives, the period of time will be no shorter than one year.
(d) Each such grant or sale will provide that during or after the period for which such substantial risk of forfeiture is to continue, the transferability of the Restricted Stock will be prohibited or restricted in the manner and to the extent prescribed by the Committee at the Date of Grant (which restrictions may include, without limitation, rights of repurchase or first refusal in the Company or provisions subjecting the Restricted Stock to a continuing substantial risk of forfeiture in the hands of any transferee).
(e) Any grant of Restricted Stock may specify Management Objectives that, if achieved, will result in termination or early termination of the restrictions applicable to such Restricted Stock; provided, however, that notwithstanding subparagraph (c) above, restrictions relating to Restricted Stock that vests upon the achievement of Management Objectives may not terminate sooner than one year. Each grant may specify in respect of such Management Objectives a minimum acceptable level of achievement and may set
|
|
|
|
|
2025 Proxy Statement 113 |
Appendix A: Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
forth a formula for determining the number of shares of Restricted Stock on which restrictions will terminate if performance is at or above the minimum or threshold level or levels, or is at or above the target level or levels, but falls short of maximum achievement of the specified Management Objectives.
(f) Notwithstanding anything to the contrary contained in this Plan, any grant or sale of Restricted Stock may provide for the earlier termination of restrictions on such Restricted Stock (i) in the event of the retirement, death or disability of a Participant or (ii) in the event of a Change in Control where either (A) within a specified period the Participant is involuntarily terminated for reasons other than for cause or terminates his or her employment for good reason or (B) such Restricted Stock is not assumed or converted into replacement awards in a manner described in the Evidence of Award.
(g) Any such grant or sale of Restricted Stock may require that any or all dividends or other distributions paid thereon during the period of such restrictions be automatically deferred and reinvested in additional Restricted Stock, which may be subject to the same restrictions as the underlying award; provided, however, that dividends or other distributions on Restricted Stock with restrictions that lapse as a result of the achievement of Management Objectives will be deferred until and paid contingent upon the achievement of the applicable Management Objectives.
(h) Each grant or sale of Restricted Stock will be evidenced by an Evidence of Award and will contain such terms and provisions, consistent with this Plan, as the Committee may approve. Unless otherwise directed by the Committee, (i) all certificates representing Restricted Stock will be held in custody by the Company until all restrictions thereon will have lapsed, together with a stock power or powers executed by the Participant in whose name such certificates are registered, endorsed in blank and covering such shares or (ii) all Restricted Stock will be held at the Company’s transfer agent in book entry form with appropriate restrictions relating to the transfer of such Restricted Stock.”
13. Section 7 of the Plan shall be, and hereby is, amended such that the Section shall hereby read as follows:
“Restricted Stock Units: The Committee may, from time to time and upon such terms and conditions as it may determine, authorize the granting or sale of Restricted Stock Units to Participants. Each such grant or sale may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the following provisions:
(a) Each such grant or sale will constitute the agreement by the Company to deliver Common Stock or cash to the Participant in the future in consideration of the performance of services, but subject to the fulfillment of such conditions (which may include the achievement of Management Objectives) during the Restriction Period as the Committee may specify. If a grant of Restricted Stock Units specifies that the Restriction Period will terminate only upon the achievement of Management Objectives or that the Restricted Stock Units will be earned based on the achievement of Management Objectives, then, notwithstanding anything to the contrary contained in subparagraph (c) below, the applicable Restriction Period may not be a period of less than one year. Each grant may specify in respect of such Management Objectives a minimum acceptable level of achievement and may set forth a formula for determining the number of Restricted Stock Units on which restrictions will terminate if performance is at or above the minimum or threshold level or levels, or is at or above the target level or levels, but falls short of maximum achievement of the specified Management Objectives.
(b) Each such grant or sale may be made without additional consideration or in consideration of a payment by such Participant that is less than the Market Value per Share at the Date of Grant.
(c) If the Restriction Period lapses only by the passage of time rather than the achievement of Management Objectives as provided in subparagraph (a) above, each such grant or sale will be subject to a Restriction Period of not less than one year.
(d) Notwithstanding anything to the contrary contained in this Plan, any grant or sale of Restricted Stock Units may provide for the earlier lapse or other modification of the Restriction Period (i) in the event of the retirement, death or disability of a Participant or (ii) in the event of a Change in Control where either (A) within a specified period the Participant is involuntarily terminated for reasons other than for cause or terminates his or her employment for good reason or (B) such Restricted Stock Units are not assumed or converted into replacement awards in a manner described in the Evidence of Award.
|
|
|
114 2025 Proxy Statement |
|
|
Appendix A: Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
(e) During the Restriction Period, the Participant will have no right to transfer any rights under his or her award and will have no rights of ownership in the Common Stock deliverable upon payment of the Restricted Stock Units and will have no right to vote them, but the Committee may, at the Date of Grant, authorize the payment of dividend equivalents on such Restricted Stock Units on either a current or deferred or contingent basis, either in cash or in additional Common Stock; provided, however, that dividend equivalents or other distributions on Common Stock underlying Restricted Stock Units with restrictions that lapse as a result of the achievement of Management Objectives will be deferred until and paid contingent upon the achievement of the applicable Management Objectives.
(f) Each grant or sale of Restricted Stock Units will specify the time and manner of payment of the Restricted Stock Units that have been earned. Each grant or sale will specify that the amount payable with respect thereto will be paid by the Company in Common Stock or cash, or a combination thereof.
(g) Each grant or sale of Restricted Stock Units will be evidenced by an Evidence of Award and will contain such terms and provisions, consistent with this Plan, as the Committee may approve.”
14. Section 8 of the Plan shall be, and hereby is, amended such that the Section shall hereby read as follows:
“Cash Incentive Awards, Performance Shares and Performance Units. The Committee may, from time to time and upon such terms and conditions as it may determine, authorize the granting of Cash Incentive Awards, Performance Shares and Performance Units. Each such grant may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the following provisions:
(a) Each grant will specify the number or amount of Performance Shares or Performance Units, or amount payable with respect to Cash Incentive Awards, to which it pertains, which number or amount may be subject to adjustment to reflect changes in compensation or other factors.
(b) The Performance Period with respect to each Cash Incentive Award, Performance Share or Performance Unit will be such period of time (not less than one year for Performance Shares and Performance Units) as will be determined by the Committee at the time of grant, which may be subject to earlier lapse or other modification (i) in the event of the retirement, death or disability of a Participant or (ii) in the event of a Change in Control where either (A) within a specified period the Participant is involuntarily terminated for reasons other than for cause or terminates his or her employment for good reason or (B) such Cash Incentive Awards, Performance Shares and Performance Units are not assumed or converted into replacement awards in a manner described in the Evidence of Award.
(c) Any grant of Cash Incentive Awards, Performance Shares or Performance Units will specify Management Objectives which, if achieved, will result in payment or early payment of the award, and each grant may specify in respect of such specified Management Objectives a minimum acceptable level or levels of achievement and may set forth a formula for determining the number of Performance Shares or Performance Units, or amount payable with respect to Cash Incentive Awards, that will be earned if performance is at or above the minimum or threshold level or levels, or is at or above the target level or levels, but falls short of maximum achievement of the specified Management Objectives. The grant of a Cash Incentive Award, Performance Shares or Performance Units will specify that, before the Cash Incentive Award, Performance Shares or Performance Units will be earned and paid, the Committee must determine that the Management Objectives have been satisfied.
(d) Each grant will specify the time and manner of payment of Cash Incentive Awards, Performance Shares or Performance Units that have been earned. Any grant may specify that the amount payable with respect thereto may be paid by the Company in cash, in Common Stock, in Restricted Stock or Restricted Stock Units or in any combination thereof.
(e) Any grant of Cash Incentive Awards, Performance Shares or Performance Units may specify that the amount payable or the number of shares of Common Stock or Restricted Stock or Restricted Stock Units with respect thereto may not exceed a maximum specified by the Committee at the Date of Grant.
(f) The Committee may, at the Date of Grant of Performance Shares, provide for the payment of dividend equivalents to the holder thereof either in cash or in additional Common Stock, subject in all cases to deferral and payment on a contingent basis based on the Participant’s earning of the Performance Shares with respect to which such dividend equivalents are paid.
(g) Each grant of Cash Incentive Awards, Performance Shares or Performance Units will be evidenced by an Evidence of Award and will contain such other terms and provisions, consistent with this Plan, as the Committee may approve.”
|
|
|
|
|
2025 Proxy Statement 115 |
Appendix A: Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan
15. Sections 9(d) and 9(e) of the Plan shall be, and hereby are, amended such that these Sections shall hereby read as follows:
“(d) If the earning or vesting of, or elimination of restrictions applicable to, an award granted under this Section 9 is based only on the passage of time rather than the achievement of Management Objectives, the period of time shall be no shorter than one year. If the earning or vesting of, or elimination of restrictions applicable to, awards granted under this Section 9 is based on the achievement of Management Objectives, the earning, vesting or restriction period may not terminate sooner than one year from the Date of Grant.
(e) Notwithstanding anything to the contrary contained in this Plan, any grant of an award under this Section 9 may provide for the earning or vesting of, or earlier elimination of restrictions applicable to, such award (i) in the event of the retirement, death or disability of the Participant, or (ii) in the event of a Change in Control where either (A) within a specified period the Participant is involuntarily terminated for reasons other than for cause or terminates his or her employment for good reason or (B) such awards are not assumed or converted into replacement awards in a manner described in the Evidence of Award.”
16. Section 10(c) of the Plan shall be, and hereby is, amended, such that subsection (A) of such section shall hereby read as follows:
“the Committee will not delegate such responsibilities to any such officer for awards granted to an employee who is an officer, Director, or more than 10% beneficial owner of any class of the Company’s equity securities that is registered pursuant to Section 12 of the Exchange Act, as determined by the Committee in accordance with Section 16 of the Exchange Act.”
17. Section 18(c) of the Plan shall be, and hereby is, amended, such that such section shall hereby read as follows:
“If permitted by Section 409A of the Code, but subject to the paragraph that follows, in the case of termination of employment by reason of death, disability or retirement, or in the event of a Change in Control, to the extent a Participant holds an Option Right or Appreciation Right not immediately exercisable in full, or any Restricted Stock as to which the substantial risk of forfeiture or the prohibition or restriction on transfer has not lapsed, or any Restricted Stock Units as to which the Restriction Period has not been completed, or any Cash Incentive Awards, Performance Shares or Performance Units which have not been fully earned, or any other awards made pursuant to Section 9 subject to any vesting schedule or transfer restriction, or who holds Common Stock subject to any transfer restriction imposed pursuant to Section 15(b) of this Plan, the Committee may, in its sole discretion, accelerate the time at which such Option Right, Appreciation Right or other award may be exercised or the time at which such substantial risk of forfeiture or prohibition or restriction on transfer will lapse or the time when such Restriction Period will end or the time at which such Cash Incentive Awards, Performance Shares or Performance Units will be deemed to have been fully earned or the time when such transfer restriction will terminate or may waive any other limitation or requirement under any such award.
Subject to Section 18(b) hereof, the Committee may amend the terms of any award theretofore granted under this Plan prospectively or retroactively. Subject to Section 11 above, no such amendment will impair the rights of any Participant without his or her consent. The Board may, in its discretion, terminate this Plan at any time. Termination of this Plan will not affect the rights of Participants or their successors under any awards outstanding hereunder and not exercised in full on the date of termination.”
18. Section 20 of the Plan shall be, and hereby is, amended to extend the expiration date of the Plan for an additional two years, such that the third and final sentence of such section shall hereby read as follows:
“No grant will be made under this Plan after April 19, 2030, but all grants made on or prior to such date will continue in effect thereafter subject to the terms thereof and of this Plan.”
19. In all other respects, the Plan, as amended, is hereby ratified and confirmed and shall remain in full force and effect.
IN WITNESS WHEREOF, the Corporation has executed this Amendment No. 5 to the 2013 Equity and Incentive Compensation Plan.
|
|
|
ENVIRI CORPORATION |
|
|
By: |
|
|
|
Name: Russell C. Hochman |
Title: Corporate Secretary |
|
|
|
116 2025 Proxy Statement |
|
|
Appendix B: Amendment No. 3 to the 2016
Non-Employee Directors’ Long-Term Equity Compensation Plan
ENVIRI CORPORATION
2016 NON-EMPLOYEE DIRECTORS’ LONG-TERM EQUITY COMPENSATION PLAN
Amendment No. 3
WHEREAS, the Board of Directors and stockholders of Enviri Corporation (the “Corporation”) have adopted the 2016 Non-Employee Directors’ Long-Term Equity Compensation Plan, as amended by Amendment No. 1 and Amendment No. 2 thereto (the “Plan”);
WHEREAS, pursuant to Section IV.A. of the Plan, a total of 400,000 shares of the common stock, par value $1.25 per share, of the Corporation (the “Common Stock”) have been reserved for issuance under the Plan;
WHEREAS, the Corporation desires to increase the number of shares issuable under the Plan to an aggregate of 1,200,000 shares, including shares previously issued thereunder; and
WHEREAS, Section XIII of the Plan permits the Corporation to amend the Plan from time to time, subject only to certain limitations specified therein;
NOW, THEREFORE, the following amendment and modification is hereby made a part of the Plan subject to, and effective as of the date of, the approval of stockholders of the Plan as amended at the Corporation’s Annual Meeting of Stockholders on April 24, 2025:
1. Section II.H of the Plan shall be, and hereby is, amended to change the definition of “Company” to Enviri Corporation.
2. Section II.J of the Plan shall be, and hereby is, amended to change the definition of “Disability” to read as follows:
““Disability” with respect to any Award, means any illness or other physical or mental condition of a Participant that renders the Participant incapable of performing his or her customary and usual duties for the Company (with or without a reasonable accommodation as required by law) and that in the judgment of the Committee is permanent and continuous in nature. The Committee may establish any process or procedure it deems appropriate for determining whether a Participant has a “Disability”.”
3. Section III.B of the Plan shall be, and hereby is, amended such that the below clause in the first sentence of such section shall hereby read as follows:
“and (subject to the provisions of Article XIII herein) amend, but not accelerate, the terms and conditions of any outstanding Award to the extent such terms and conditions are within the discretion of the Committee as provided in the Plan.”
4. Section IV.A of the Plan shall be, and hereby is, amended such that the first sentence of such section shall hereby read as follows:
“Subject to Sections IV.B and IV.C herein, the maximum number of Shares with respect to which Awards may be granted to Participants under the Plan shall be one million two hundred thousand (1,200,000) shares.”
5. Section VIII.D of the Plan shall be, and hereby is, amended, such that the first sentence of such section shall hereby read as follows:
“Subject to the terms hereof, the Committee may impose such other conditions and/or restrictions on any Shares of Restricted Stock granted pursuant to the Plan as it may deem advisable including, without limitation, a requirement that Participants pay a stipulated purchase price for each Share of Restricted Stock, time-based restrictions on vesting and/or restrictions under applicable federal or state securities laws.”
|
|
|
|
|
2025 Proxy Statement 117 |
Pay vs Performance Disclosure - USD ($)
|
12 Months Ended |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Pay vs Performance Disclosure |
|
|
|
|
|
Pay vs Performance Disclosure, Table |
Pay Versus Performance Disclosure In accordance with rules adopted by the Securities and Exchange Commission (“SEC”) pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive “compensation actually paid” (“CAP”) and certain Company performance for the fiscal years listed below. You should refer to our Compensation Discussion & Analysis (“CD&A”) for a complete description of how executive compensation relates to Company performance and how the Compensation Committee makes its decisions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Compensation Table Total for PEO (2) |
|
|
|
|
|
Average Compensation Actually Paid for Non-PEO NEOs (3) |
|
Value of Initial Fixed $100 Investment based on: |
|
|
|
Company Selected Measure (7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
$6,266 |
|
$3,589 |
|
$2,036 |
|
$1,637 |
|
33.46 |
|
203.37 |
|
($103,046) |
|
$89,547 |
|
|
|
|
|
|
|
|
|
2023 |
|
$6,599 |
|
$7,749 |
|
$2,132 |
|
$2,217 |
|
39.11 |
|
147.49 |
|
($84,297) |
|
$91,608 |
|
|
|
|
|
|
|
|
|
2022 |
|
$5,926 |
|
($1,399) |
|
$1,246 |
|
$136 |
|
27.34 |
|
113.61 |
|
($176,431) |
|
$57,946 |
|
|
|
|
|
|
|
|
|
2021 |
|
$5,394 |
|
$1,521 |
|
$1,307 |
|
$858 |
|
72.62 |
|
123.67 |
|
$2,729 |
|
$41,858 |
|
|
|
|
|
|
|
|
|
2020 |
|
$3,793 |
|
$5,709 |
|
$1,113 |
|
$1,268 |
|
78.14 |
|
112.44 |
|
($21,975) |
|
$35,177 |
(1) |
Amounts reported per year include only data reported for the NEOs for the corresponding year. |
(2) |
The amounts reported in this column correspond to the amounts reported in the Company’s Proxy Statement Summary Compensation Table (“SCT”). The PEO in each covered year is Mr. Grasberger. The non-PEO NEOs for whom the average compensation is presented in this table for fiscal year 2025 are Messrs. Vadaketh, Hochman, Beswick, and Ms. Kozak. For 2023, Messrs. Vadaketh, Minan, Hochman, Beswick, and Ms. Kozak, and Mr. Mitchell. For 2022, Messrs. Minan, Aga, Hochman, Mitchell, Ms. Kozak, Mr. Stanton, and Ms. Livingston. For 2021, the NEOs include Messrs. Minan, Aga, Hochman, Stanton, and Ms. Livingston. For 2020, the NEOs include Messrs. Minan, Hochman, Stanton, Ms. Livingston, and Ms. McKenzie. |
(3) |
PEO and non-PEO NEO CAP was calculated as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Compensation Table Total |
|
|
|
|
|
|
|
|
|
F. Nicholas Grasberger III, CEO serving as the PEO |
|
|
|
|
|
|
|
|
|
|
|
$6,266,045 |
|
|
|
$1,704,164 |
|
|
$3,589,056 |
|
|
|
|
|
|
|
|
$6,598,650 |
|
($4,374,308) |
|
$5,525,031 |
|
|
$7,749,373 |
|
|
|
|
|
|
|
|
$5,926,007 |
|
($3,938,251) |
|
($3,386,836) |
|
|
($1,399,081) |
|
|
|
|
|
|
|
|
$5,393,717 |
|
($3,920,447) |
|
$47,772 |
|
|
$1,521,043 |
|
|
|
|
|
|
|
|
$3,793,021 |
|
($2,173,365) |
|
$4,089,080 |
|
|
$5,708,736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$2,036,377 |
|
($1,035,406) |
|
$635,679 |
|
|
$1,636,651 |
|
|
|
|
|
|
|
|
$2,131,871 |
|
($915,230) |
|
$1,000,131 |
|
|
$2,216,771 |
|
|
|
|
|
|
|
|
$1,245,591 |
|
($630,208) |
|
($479,135) |
|
|
$136,248 |
|
|
|
|
|
|
|
|
$1,307,238 |
|
($612,034) |
|
$162,649 |
|
|
$857,853 |
|
|
|
|
|
|
|
|
$1,112,707 |
|
($472,960) |
|
$627,920 |
|
|
$1,267,667 |
|
|
(a) |
The additions to the SCT includes the year-end Fair Market Value (“FMV”) of the awards granted for the applicable year plus or minus the annual change in the FMV as of the year-end for unvested awards granted in prior years as well as plus or minus the change in the FMV as of the date of vesting for awards vested in each applicable year versus the ending stock price of the prior year. The FMV of each PSU grant was estimated on the measurement date using a Monte Carlo pricing model and is reported on the table below. In addition, the FMV for each SAR grant was estimated on the measurement date using a Black Scholes pricing model; details noted below. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Price @ Valuation Date |
|
|
|
Stock Price @ Valuation Date |
|
|
|
Stock Price @ Valuation Date |
|
|
|
Stock Price @ Valuation Date |
|
|
|
Stock Price @ Valuation Date |
|
|
|
Stock Price @ Valuation Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/2/2018 |
|
$35.24 |
|
$23.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12/31/2020 |
|
$17.98 |
|
|
|
|
|
|
|
|
|
|
|
|
7/30/2018 |
|
$35.24 |
|
$23.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12/31/2020 |
|
$17.98 |
|
|
|
|
|
|
|
|
|
|
|
|
3/6/2019 |
|
$25.78 |
|
$23.01 |
|
$15.71 |
|
$17.98 |
|
|
|
|
|
|
|
|
|
|
|
12/31/2021 |
|
$16.71 |
|
|
|
|
|
|
|
|
|
|
|
|
3/10/2020 |
|
|
|
|
|
$20.69 |
|
$17.98 |
|
$6.48 |
|
$16.71 |
|
|
|
|
|
|
|
12/31/2022 |
|
$6.29 |
|
|
|
|
|
|
|
|
|
|
|
|
10/19/2020 |
|
|
|
|
|
$20.69 |
|
$17.98 |
|
$6.48 |
|
$16.71 |
|
|
|
|
|
|
|
12/31/2022 |
|
$6.29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
3/1/2021 |
|
|
|
|
|
|
|
|
|
$19.52 |
|
$16.71 |
|
$1.26 |
|
$6.29 |
|
|
|
|
|
12/31/2023 |
|
$9.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/4/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$3.58 |
|
$6.29 |
|
$1.89 |
|
$9.00 |
|
|
|
|
|
12/31/2024 |
|
$7.70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/7/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$13.12 |
|
$9.00 |
|
$7.67 |
|
$7.70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5/9/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$13.12 |
|
$9.00 |
|
$7.67 |
|
$7.70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/11/2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$9.86 |
|
$7.70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Appreciation Rights |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Price At Measurement Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/3/2017 |
|
12/31/2019 |
|
$23.01 |
|
$13.70 |
|
1.64% |
|
45.64% |
|
3.68 |
|
$12.29 |
|
|
|
|
|
|
|
|
3/3/2017 |
|
3/3/2020 |
|
$11.40 |
|
$13.70 |
|
0.75% |
|
55.49% |
|
4.15 |
|
$4.39 |
|
|
|
|
|
|
|
|
3/2/2018 |
|
12/31/2019 |
|
$23.01 |
|
$19.80 |
|
1.66% |
|
53.19% |
|
4.42 |
|
$11.24 |
|
|
|
|
|
|
|
|
3/2/2018 |
|
3/2/2020 |
|
$12.18 |
|
$19.80 |
|
0.92% |
|
51.43% |
|
5.71 |
|
$4.22 |
|
|
|
|
|
|
|
|
3/2/2018 |
|
12/31/2020 |
|
$17.98 |
|
$19.80 |
|
0.27% |
|
61.39% |
|
4.03 |
|
$7.90 |
|
|
|
|
|
|
|
|
3/2/2018 |
|
3/2/2021 |
|
$17.02 |
|
$19.80 |
|
0.47% |
|
62.83% |
|
4.05 |
|
$7.45 |
|
|
|
|
|
|
|
|
7/30/2018 |
|
12/31/2019 |
|
$23.01 |
|
$24.65 |
|
1.69% |
|
51.20% |
|
5.11 |
|
$10.17 |
|
|
|
|
|
|
|
|
7/30/2018 |
|
7/30/2020 |
|
$15.83 |
|
$24.65 |
|
0.28% |
|
61.33% |
|
5.59 |
|
$6.82 |
|
|
|
|
|
|
|
|
7/30/2018 |
|
12/31/2020 |
|
$17.98 |
|
$24.65 |
|
0.38% |
|
63.67% |
|
5.14 |
|
$8.25 |
|
|
|
|
|
|
|
|
7/30/2018 |
|
7/30/2021 |
|
$20.12 |
|
$24.65 |
|
0.56% |
|
61.85% |
|
4.21 |
|
$8.60 |
|
|
|
|
|
|
|
|
3/6/2019 |
|
12/31/2019 |
|
$23.01 |
|
$22.51 |
|
1.70% |
|
50.99% |
|
5.18 |
|
$10.80 |
|
|
|
|
|
|
|
|
3/6/2019 |
|
3/6/2020 |
|
$10.29 |
|
$22.51 |
|
0.69% |
|
47.34% |
|
7.21 |
|
$2.97 |
|
|
|
|
|
|
|
|
3/6/2019 |
|
12/31/2020 |
|
$17.98 |
|
$22.51 |
|
0.40% |
|
63.37% |
|
5.27 |
|
$8.72 |
|
|
|
|
|
|
|
|
3/6/2019 |
|
3/6/2021 |
|
$16.95 |
|
$22.51 |
|
0.81% |
|
64.52% |
|
5.10 |
|
$8.08 |
|
|
|
|
|
|
|
|
3/6/2019 |
|
12/31/2021 |
|
$16.71 |
|
$22.51 |
|
1.21% |
|
61.11% |
|
4.69 |
|
$7.19 |
|
|
|
|
|
|
|
|
3/6/2019 |
|
3/6/2022 |
|
$12.65 |
|
$22.51 |
|
1.65% |
|
61.30% |
|
5.20 |
|
$5.01 |
|
|
|
|
|
|
|
|
3/10/2020 |
|
12/31/2020 |
|
$17.98 |
|
$10.29 |
|
0.39% |
|
63.45% |
|
5.19 |
|
$11.86 |
|
|
|
|
|
|
|
|
3/10/2020 |
|
3/10/2021 |
|
$18.10 |
|
$10.29 |
|
0.68% |
|
61.17% |
|
4.50 |
|
$11.44 |
|
|
|
|
|
|
|
|
3/10/2020 |
|
12/31/2021 |
|
$16.71 |
|
$10.29 |
|
1.18% |
|
61.69% |
|
4.44 |
|
$10.34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Appreciation Rights |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Price At Measurement Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/10/2020 |
|
3/10/2022 |
|
$13.46 |
|
$10.29 |
|
1.89% |
|
65.65% |
|
4.00 |
|
$7.74 |
|
|
|
|
|
|
|
|
3/10/2020 |
|
12/31/2022 |
|
$6.29 |
|
$10.29 |
|
3.95% |
|
64.86% |
|
5.21 |
|
$2.98 |
|
|
|
|
|
|
|
|
3/10/2020 |
|
3/10/2023 |
|
$7.41 |
|
$10.29 |
|
3.99% |
|
67.69% |
|
4.59 |
|
$3.69 |
|
|
|
|
|
|
|
|
10/19/2020 |
|
12/31/2020 |
|
$17.98 |
|
$14.89 |
|
0.48% |
|
61.60% |
|
5.80 |
|
$10.62 |
|
|
|
|
|
|
|
|
10/19/2020 |
|
10/19/2021 |
|
$16.97 |
|
$14.89 |
|
1.05% |
|
61.00% |
|
4.50 |
|
$8.96 |
|
|
|
|
|
|
|
|
10/19/2020 |
|
12/31/2021 |
|
$16.71 |
|
$14.89 |
|
1.26% |
|
59.97% |
|
5.05 |
|
$9.09 |
|
|
|
|
|
|
|
|
10/19/2020 |
|
10/19/2022 |
|
$4.51 |
|
$14.89 |
|
4.07% |
|
63.01% |
|
7.10 |
|
$1.85 |
|
|
|
|
|
|
|
|
10/19/2020 |
|
12/31/2022 |
|
$6.29 |
|
$14.89 |
|
3.93% |
|
61.42% |
|
6.55 |
|
$2.73 |
|
|
|
|
|
|
|
|
3/1/2021 |
|
12/31/2021 |
|
$16.71 |
|
$18.58 |
|
1.31% |
|
59.08% |
|
5.62 |
|
$8.49 |
|
|
|
|
|
|
|
|
3/1/2021 |
|
3/1/2022 |
|
$12.01 |
|
$18.58 |
|
1.62% |
|
63.29% |
|
6.27 |
|
$5.99 |
|
|
|
|
|
|
|
|
3/1/2021 |
|
12/31/2022 |
|
$6.29 |
|
$18.58 |
|
3.92% |
|
63.66% |
|
7.18 |
|
$2.78 |
|
|
|
|
|
|
|
|
3/1/2021 |
|
3/1/2023 |
|
$8.41 |
|
$18.58 |
|
4.15% |
|
61.26% |
|
6.43 |
|
$3.75 |
|
|
|
|
|
|
|
|
3/1/2021 |
|
12/31/2023 |
|
$9.00 |
|
$18.58 |
|
3.82% |
|
64.42% |
|
5.67 |
|
$3.98 |
|
|
|
|
|
|
|
|
3/1/2021 |
|
3/1/2024 |
|
$8.26 |
|
$18.58 |
|
4.14% |
|
64.45% |
|
5.66 |
|
$3.52 |
|
|
|
|
|
|
|
|
3/4/2022 |
|
12/31/2022 |
|
$6.29 |
|
$12.65 |
|
3.91% |
|
63.45% |
|
7.41 |
|
$3.34 |
|
|
|
|
|
|
|
|
3/4/2022 |
|
3/4/2023 |
|
$8.37 |
|
$12.65 |
|
4.15% |
|
61.82% |
|
6.19 |
|
$4.38 |
|
|
|
|
|
|
|
|
3/4/2022 |
|
12/31/2023 |
|
$9.00 |
|
$12.65 |
|
3.82% |
|
64.47% |
|
5.63 |
|
$4.75 |
|
|
|
|
|
|
|
|
3/4/2022 |
|
3/4/2024 |
|
$8.27 |
|
$12.65 |
|
4.17% |
|
65.02% |
|
5.54 |
|
$4.24 |
|
|
|
|
|
|
|
|
3/4/2022 |
|
12/31/2024 |
|
$7.70 |
|
$12.65 |
|
4.34% |
|
66.91% |
|
5.20 |
|
$3.80 |
|
|
|
|
|
|
|
|
3/7/2023 |
|
12/31/2023 |
|
$9.00 |
|
$7.45 |
|
3.81% |
|
66.53% |
|
5.19 |
|
$5.72 |
|
|
|
|
|
|
|
|
3/7/2023 |
|
3/7/2024 |
|
$8.33 |
|
$7.45 |
|
4.08% |
|
68.16% |
|
4.50 |
|
$4.98 |
|
|
|
|
|
|
|
|
3/7/2023 |
|
12/31/2024 |
|
$7.70 |
|
$7.45 |
|
4.30% |
|
58.60% |
|
4.43 |
|
$4.02 |
|
|
|
|
|
|
|
|
5/9/2023 |
|
12/13/2023 |
|
$9.00 |
|
$9.31 |
|
3.81% |
|
64.92% |
|
5.51 |
|
$5.33 |
|
|
|
|
|
|
|
|
5/9/2023 |
|
5/9/2024 |
|
$8.30 |
|
$9.31 |
|
4.42% |
|
66.97% |
|
5.04 |
|
$4.75 |
|
|
|
|
|
|
|
|
5/9/2023 |
|
12/13/2024 |
|
$7.70 |
|
$9.31 |
|
4.35% |
|
66.45% |
|
5.33 |
|
$4.36 |
|
|
|
|
|
|
|
|
3/11/2024 |
|
12/13/2024 |
|
$7.70 |
|
$8.20 |
|
4.36% |
|
66.36% |
|
5.47 |
|
$4.62 |
|
(i) |
Stock Prices reported equal the company’s year-end stock price for the vesting dates noted. |
|
(ii) |
The March 2020 grant FMV was estimated on measurement date using a Monte Carlo simulation because exercise price is greater than the FMV of Enviri Common Stock on the grant date. |
(4) |
Enviri’s and the Peer Group’s Total Stockholders Return (“TSR”) is based on investing $100 on December 31, 2019. |
(5) |
The Peer Group utilized is the Dow Jones US Diversified Industrials. |
(6) |
Amounts reflect the Net Income (Loss) of the Company as reported in the Form 10-K Annual Report for the corresponding fiscal years of 2024, 2023, 2022, 2021 and 2020. |
(7) |
Amounts reflect the adjusted Enviri Business Unit Contribution (BUC) as reported in the Company’s Proxy Statement for the years 2024, 2023, 2022, 2021 and 2020. For further details, please refer to the “AIP Performance Metrics and Payouts” section in the CD&A. |
|
|
|
|
|
Company Selected Measure Name |
Business Unit Contribution (BUC)
|
|
|
|
|
Named Executive Officers, Footnote |
(2) |
The amounts reported in this column correspond to the amounts reported in the Company’s Proxy Statement Summary Compensation Table (“SCT”). The PEO in each covered year is Mr. Grasberger. The non-PEO NEOs for whom the average compensation is presented in this table for fiscal year 2025 are Messrs. Vadaketh, Hochman, Beswick, and Ms. Kozak. For 2023, Messrs. Vadaketh, Minan, Hochman, Beswick, and Ms. Kozak, and Mr. Mitchell. For 2022, Messrs. Minan, Aga, Hochman, Mitchell, Ms. Kozak, Mr. Stanton, and Ms. Livingston. For 2021, the NEOs include Messrs. Minan, Aga, Hochman, Stanton, and Ms. Livingston. For 2020, the NEOs include Messrs. Minan, Hochman, Stanton, Ms. Livingston, and Ms. McKenzie. |
|
|
|
|
|
Peer Group Issuers, Footnote |
The Peer Group utilized is the Dow Jones US Diversified Industrials.
|
|
|
|
|
PEO Total Compensation Amount |
$ 6,266,045
|
$ 6,598,650
|
$ 5,926,007
|
$ 5,393,717
|
$ 3,793,021
|
PEO Actually Paid Compensation Amount |
$ 3,589,056
|
7,749,373
|
(1,399,081)
|
1,521,043
|
5,708,736
|
Adjustment To PEO Compensation, Footnote |
(3) |
PEO and non-PEO NEO CAP was calculated as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Compensation Table Total |
|
|
|
|
|
|
|
|
|
F. Nicholas Grasberger III, CEO serving as the PEO |
|
|
|
|
|
|
|
|
|
|
|
$6,266,045 |
|
|
|
$1,704,164 |
|
|
$3,589,056 |
|
|
|
|
|
|
|
|
$6,598,650 |
|
($4,374,308) |
|
$5,525,031 |
|
|
$7,749,373 |
|
|
|
|
|
|
|
|
$5,926,007 |
|
($3,938,251) |
|
($3,386,836) |
|
|
($1,399,081) |
|
|
|
|
|
|
|
|
$5,393,717 |
|
($3,920,447) |
|
$47,772 |
|
|
$1,521,043 |
|
|
|
|
|
|
|
|
$3,793,021 |
|
($2,173,365) |
|
$4,089,080 |
|
|
$5,708,736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$2,036,377 |
|
($1,035,406) |
|
$635,679 |
|
|
$1,636,651 |
|
|
|
|
|
|
|
|
$2,131,871 |
|
($915,230) |
|
$1,000,131 |
|
|
$2,216,771 |
|
|
|
|
|
|
|
|
$1,245,591 |
|
($630,208) |
|
($479,135) |
|
|
$136,248 |
|
|
|
|
|
|
|
|
$1,307,238 |
|
($612,034) |
|
$162,649 |
|
|
$857,853 |
|
|
|
|
|
|
|
|
$1,112,707 |
|
($472,960) |
|
$627,920 |
|
|
$1,267,667 |
|
|
|
|
|
|
Non-PEO NEO Average Total Compensation Amount |
$ 2,036,377
|
2,131,871
|
1,245,591
|
1,307,238
|
1,112,707
|
Non-PEO NEO Average Compensation Actually Paid Amount |
$ 1,636,651
|
2,216,771
|
136,248
|
857,853
|
1,267,667
|
Adjustment to Non-PEO NEO Compensation Footnote |
(3) |
PEO and non-PEO NEO CAP was calculated as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Compensation Table Total |
|
|
|
|
|
|
|
|
|
F. Nicholas Grasberger III, CEO serving as the PEO |
|
|
|
|
|
|
|
|
|
|
|
$6,266,045 |
|
|
|
$1,704,164 |
|
|
$3,589,056 |
|
|
|
|
|
|
|
|
$6,598,650 |
|
($4,374,308) |
|
$5,525,031 |
|
|
$7,749,373 |
|
|
|
|
|
|
|
|
$5,926,007 |
|
($3,938,251) |
|
($3,386,836) |
|
|
($1,399,081) |
|
|
|
|
|
|
|
|
$5,393,717 |
|
($3,920,447) |
|
$47,772 |
|
|
$1,521,043 |
|
|
|
|
|
|
|
|
$3,793,021 |
|
($2,173,365) |
|
$4,089,080 |
|
|
$5,708,736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$2,036,377 |
|
($1,035,406) |
|
$635,679 |
|
|
$1,636,651 |
|
|
|
|
|
|
|
|
$2,131,871 |
|
($915,230) |
|
$1,000,131 |
|
|
$2,216,771 |
|
|
|
|
|
|
|
|
$1,245,591 |
|
($630,208) |
|
($479,135) |
|
|
$136,248 |
|
|
|
|
|
|
|
|
$1,307,238 |
|
($612,034) |
|
$162,649 |
|
|
$857,853 |
|
|
|
|
|
|
|
|
$1,112,707 |
|
($472,960) |
|
$627,920 |
|
|
$1,267,667 |
|
|
|
|
|
|
Compensation Actually Paid vs. Total Shareholder Return |
CAP and Cumulative TSR / Cumulative TSR of the Peer Group
|
|
|
|
|
Compensation Actually Paid vs. Net Income |
CAP and Company Net Income
|
|
|
|
|
Compensation Actually Paid vs. Company Selected Measure |
For more information a bou t BUC, please refer to the “AIP Performance Metrics and Payout” section in the CD&A.
|
|
|
|
|
Total Shareholder Return Vs Peer Group |
CAP and Cumulative TSR / Cumulative TSR of the Peer Group
|
|
|
|
|
Tabular List, Table |
Tabular List of Most Important Financial Performance Measures In our assessment, the most important financial performance measures used to link CAP (as calculated in accordance with the SEC rules), to our NEOs in 2024 to our performance were:
|
|
Tabular List of Most Important Financial Measures Used for |
|
Business Unit Contribution – (“BUC”) |
|
Relative Total Stockholder Return – (“rTSR”) |
|
|
|
|
|
Total Shareholder Return Amount |
$ 33,460
|
39,110
|
27,340
|
72,620
|
78,140
|
Peer Group Total Shareholder Return Amount |
203,370
|
147,490
|
113,610
|
123,670
|
112,440
|
Net Income (Loss) |
$ (103,046,000)
|
$ (84,297,000)
|
$ (176,431,000)
|
$ 2,729,000
|
$ (21,975,000)
|
Company Selected Measure Amount |
89,547,000
|
91,608,000
|
57,946,000
|
41,858,000
|
35,177,000
|
PEO Name |
Mr. Grasberger
|
|
|
|
|
Measure:: 1 |
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
Name |
Business Unit Contribution – (“BUC”)
|
|
|
|
|
Measure:: 2 |
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
Name |
Relative Total Stockholder Return – (“rTSR”)
|
|
|
|
|
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
Adjustment to Compensation, Amount |
$ (4,381,153)
|
$ (4,374,308)
|
$ (3,938,251)
|
$ (3,920,447)
|
$ (2,173,365)
|
PEO | SCT Total Pay [Member] |
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
Adjustment to Compensation, Amount |
1,704,164
|
5,525,031
|
(3,386,836)
|
47,772
|
4,089,080
|
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
Adjustment to Compensation, Amount |
(1,035,406)
|
(915,230)
|
(630,208)
|
(612,034)
|
(472,960)
|
Non-PEO NEO | SCT Total Pay [Member] |
|
|
|
|
|
Pay vs Performance Disclosure |
|
|
|
|
|
Adjustment to Compensation, Amount |
$ 635,679
|
$ 1,000,131
|
$ (479,135)
|
$ 162,649
|
$ 627,920
|